



Caring for People's Health

Company Presentation
28 August 2025



Important Notice

THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL.

This presentation has been prepared by STADA Arzneimittel B.V. (the "**Company**") solely for discussion and feedback purposes in relation to the Company and its future consolidated subsidiaries, including Nidda German Topco GmbH (the Company and its future consolidated subsidiaries collectively, the "Group" and referred to herein as "**we**", "**us**", "**our**", "**Group**", "**STADA Group**" or "**STADA**"). For the purpose of this disclaimer, "Presentation" shall mean and include this presentation, including any printed or electronic copies, any information provided or communicated in relation to it ("Information"). By reading the Information, you will be deemed to have (i) agreed to all of the following restrictions and made the following undertakings and (ii) acknowledged that you understand the legal and regulatory sanctions attached to the misuse, disclosure or improper circulation of the Presentation.

The Information is in summary draft form, is solely for discussion and feedback purposes and must not be relied upon for any purpose. The Information does not purport to be comprehensive and has not been subject to any independent audit or review. None of the Company or its advisors (the "**Advisors**"), nor any of the Company's or the Advisors' respective shareholders (as applicable), affiliates, directors, officers, or employees, nor any other person (together the "**Persons**" and each a "**Person**") makes any representation or warranty, express or implied, as to, and accordingly no reliance should be placed on, the fairness, reasonableness, accuracy, or completeness or correctness of the Information or of the views given or implied. No Person shall have any liability whatsoever for any errors or omissions or any loss howsoever arising, directly or indirectly, from any use of this Presentation, its information or its contents or otherwise arising in connection therewith. STADA reserves the right to amend or replace the Presentation at any time and undertakes no obligation to provide the recipients with access to any additional information. The information and opinions in this Presentation are provided as of August 28, 2025 and are subject to change without notice. No Person shall be obligated to update or correct the Information. Nothing in this Presentation is, or should be relied upon as, a promise or representation as to the future. This Presentation does not purport to contain all the information that may be required to evaluate the Group and/or its financial position. No responsibility, obligation, or liability whatsoever, whether arising in tort, contract or otherwise, is or will be accepted by the Company, the Advisors or any Person for any loss, cost or damage arising from any use of the Information, or for information or opinions or for any errors, omissions or misstatements contained therein or otherwise arising in connection therewith.

Some of the Information is based on statements by third parties, and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, reasonableness, accuracy, completeness or correctness of this Information or any other information or opinions contained herein, for any purpose whatsoever.

This Presentation does not constitute or form part of, and should not be construed as, an offer or invitation or inducement to purchase, sell or subscribe for, underwrite or otherwise acquire, any securities of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any investment decision, contract to purchase or subscribe for any securities of the Group, nor shall it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. This document is neither a prospectus for the purposes of Article 3 of Regulation 2017/1129/EU, as amended ("**Prospectus Regulation**"), nor a prospectus under any other applicable laws.

Important Notice

The information contained in this Presentation is not to be viewed from nor for publication or distribution in nor taken or transmitted into the United States of America, its territories and possessions, any State of the United States, and the District of Columbia ("**United States**"), Australia, Canada or Japan and does not constitute or form part of, and should not be construed as, an offer or the solicitation of an offer to subscribe for or purchase securities of the Company or any other Group entity in any of these jurisdictions or elsewhere. Any securities offered by the Group have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "**Securities Act**"), or the securities laws of any state or other jurisdiction of the United States, and such securities may not be offered, sold, pledged, taken up, exercised, resold, renounced, transferred or delivered, directly or indirectly, in or into the United States absent registration under the Securities Act, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, and in each case in accordance with any applicable state or local securities laws. There will be no public offering of securities in the United States. This Presentation does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person or in any jurisdiction.

Certain statements in this Presentation are forward-looking statements, including the presentation of data for the financial year 2025 and mid-term financial targets. Forward looking statements are statements that are not historical facts and may be identified by words such as "plans", "targets", "aims", "believes", "expects", "anticipates", "intends", "estimates", "will", "may", "continues", "should" and similar expressions. These forward-looking statements reflect, at the time, the Group's beliefs, intentions and current targets/aims concerning, among other things, the Group's results of operations, financial condition, industry, liquidity, prospects, growth and strategies and are subject to change. The estimated financial information is based on management's current expectations and is subject to change. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions, intense competition in the markets in which the Group operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting the Group's markets, and other factors beyond the control of the Group). No Person is under any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this Presentation. Statements contained in this Presentation regarding past trends or events should not be taken as a representation that such trends or events will continue in the future.

Unless stated otherwise, where historical financial or business information presented in the Information for the financial years ended December 31, 2024, 2023, 2022 and 2021 as well as for the six-month periods ended June 30, 2025 and 2024, "**we**", "**us**", "**our**", "**Group**", "**STADA Group**" or "**STADA**" refers to Nidda German Topco GmbH and its consolidated subsidiaries. The financial information for the six-month periods ended June 30, 2025 and 2024 has not been audited or reviewed, and is subject to change without notice. The financial information in this Presentation may differ from information previously published by members of the Group. The financial information in this Presentation may differ from information previously published by members of the Group. This relates to (i) the restated H1 2024 figures, as well as the restatements as described in the notes of the (ii) annual report 2024 as well as the (iii) voluntary consolidated financial statements 2021 – 2023. The Group's segment reporting implemented in 2024, which includes three segments and consolidation effects, has been retrospectively applied for the years ended December 31, 2023, 2022 and 2021 in the historical financial information used in the Information. Furthermore, results from the Group's former Russian subsidiaries, which were disposed of in 2023, are presented as discontinued operations in each of the years ended December 31, 2023, 2022 and 2021. Unless otherwise noted, the information in this Presentation relates to the Group's continuing operations.

Important Notice

This Presentation includes certain consolidated financial information of Nidda German Topco GmbH and, in addition, includes certain financial measures that are not recognized by IFRS or any other generally accepted accounting principles, including measures based on or derived from controlling data, and that may not be permitted to appear on the face of financial statements or footnotes thereto ("**Non-IFRS Measures**"), including EBITDA and Adjusted EBITDA. Non-IFRS Measures may not be comparable to, and may be calculated differently from, similarly titled measures presented by other companies. Non-IFRS Measures should not be construed as an alternative to other financial measures determined in accordance with IFRS or any other generally accepted accounting principles and have limitations as analytical tools. You are cautioned not to place undue reliance on any non-IFRS financial measures and ratios included herein. See Appendix for a reconciliation of the Non-IFRS Measures used in this Presentation to the most directly comparable IFRS measure.

Operating measures used by the Group may be based on or derived from controlling data, have limitations as analytical tools, and may not be fully comparable with the Group's results of operations, financial position, and cash flows as reported under IFRS.

No representation, warranty or undertaking, express or implied, is given by or on behalf of IQVIA Ltd. or any of its affiliated companies (together, "**IQVIA**") or their respective directors, officers, employees or agents or any other persons as to, and no reliance should be placed on, the completeness, accuracy or fairness of the information or the opinions contained therein or any other statement made or purported to be made in connection with the Company or the Group, for any purpose whatsoever, including but not limited to any investment considerations. No responsibility, obligation or liability whatsoever, whether arising in tort, contract or otherwise, is accepted or will be accepted by IQVIA or its affiliates or their respective directors, officers or employees or any other person for any loss, cost or damage howsoever arising, directly or indirectly, from any use of such information or opinions or otherwise arising in connection therewith.

To the extent available, the industry, market and competitive position data contained in this Presentation has come from official, publicly available or third party sources. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources and result from the use of methodologies believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data, which data may be subject to change and correction without notice. While the Group believes that each of these publications, studies and surveys has been prepared by a reputable source, the Group has not independently verified the data contained therein and there is no guarantee that such data has been verified by those sources. In addition, certain of the industry, market and competitive position data contained in this Presentation is based on STADA's independent analysis of multiple sources such as industry publications and surveys, industry reports prepared by consultants, internal surveys and customer feedback. The market, economic and industry data have primarily been derived and extrapolated from data and reports provided by IQVIA, Euromonitor and Evaluate Pharma. In addition, certain statistics, data and other information relating to markets, market sizes, market shares, market positions and other industry data pertaining to STADA's business and markets in this Presentation are not based on published data obtained from independent third parties or extrapolations therefrom, but rather are based upon STADA's independent analysis and best estimates, which are in turn based upon multiple third party sources, including IQVIA, Euromonitor and Evaluate Pharma and services commissioned from Boston Consulting Group; such Company analysis and best estimates is herein referred to as "**Company Data Analysis**".

Important Notice

This Presentation, where indicated, includes information from different sources. The information derived from market research information provided by IQVIA and its affiliated companies (“IQVIA”) includes data from the following data offerings: IQVIA MIDAS®, IQVIA Consumer Health Customized Insights, IQVIA Global OTC Insights, and certain national consumer health data offerings for Eurasia. Copyright IQVIA. All rights reserved. IQVIA market research information is proprietary to IQVIA and available on a confidential basis by subscription from IQVIA. IQVIA market research information reflects estimates of marketplace activity and should be treated accordingly. Many IQVIA offerings, including national audits and global offerings such as IQVIA MIDAS, reflect local industry standard source of pack prices, which might be list price or average invoice price, depending upon the country and the available information.

“IQVIA CH Customized Insights European Market Data”: IQVIA Consumer Health Customized Insights (M03 2025 release), Monthly value sales data (LEU MNF), based on pharmacy sales estimated as manufacturer (MNF) gross sales to wholesalers, limited to OTC 1-19, 97 in Austria, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia (Pharmacy only), Spain (brick&mortar Pharmacy & Parapharmacy only), Switzerland, UK. Sanofi Commercial Alliance brands included in STADA values.

“IQVIA MIDAS European Generics Market Data”: IQVIA MIDAS® (M03 2025 release), Monthly value sales data (LEU MNF), based on estimated manufacturer (MNF) gross sales to wholesalers, ATC classes A-D, G, H, J-N, P, R-T, V, all Gx prescription bound, unbranded products, Selected EU countries: Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK.

“IQVIA MIDAS European Specialty Market Data”: IQVIA MIDAS® (M03 2025 release), Monthly value sales data (LEU MNF), based on estimated manufacturer (MNF) gross sales to wholesalers, ATC classes A-D, G, H, J-N, P, R-T, V, prescription bound Specialty Gx products, prescription bound branded Gx, prescription bound biocomparable products, non-generic products of STADA, Selected EU countries: Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK.

“CHC Local Hero Brands”: Company analysis determinations of brand Top 1-3 position in CHC3 category in country based on the below data, in each case with Sanofi Commercial Alliance brands attributed to STADA: IQVIA Consumer Health Customized Insights, (M03 2025 release), CHC classes 1-19, 97, registered and non-registered products, >€500k LEU MNF in calendar year 2024, Selected EU countries: Austria, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia (Pharmacy), Spain (Pharmacy & Parapharmacy), Switzerland, UK. IQVIA Eurasian CH Data limited to Azerbaijan, Belarus, Georgia, Kazakhstan, Uzbekistan, in each case for products >€500k in calendar year 2024).

“IQVIA Eurasian CH Data”: IQVIA consumer health national data offerings in Eurasian countries as follows: Kazakhstan (2025-04), Uzbekistan (2025-04), Azerbaijan (2025-04), Belarus (2025-04), Georgia (2025-04), Moldova (2025-04), –Armenia (2025-04), Kyrgyzstan (2025-04), Bosnia & Herzegovina (2025-02).

Important Notice

"Sanofi Commercial Alliance": Involves the following brands that are presently listed in the data under Sanofi instead of STADA: (Bulgaria) Essentiale; (Estonia) Magne B6, Maalox, No Spa, Essentiale, Ipraalox, Finalgon, Dulcolax; (Finland) Bisolvon, Nasacort, Telfast, Laxoberon; (France) Mitosyl, Bronchokod; (Germany) Silomat, Sedotussin, Bronchoforton; (Ireland) Dulcolax, Pharmaton, Maalox, Opticrom, Phenergan, Nasacort, Buscopan, Telfast, Buscobiota; (Italy) Lisonatural, Lisomucil; (Latvia) Ipraalox, Dulcolax, Maalox, Magne B6, Essentiale, No Spa, Finalgon; (Lithuania) Ipraalox, Magne B6, No Spa, Finalgon, Dulcolax, Essentiale, Maalox; (Netherlands) Bisolvon, Maalox, Buscopan, Allegra, Dulcolax, Pharmaton, Mucoangin; (Norway) Lomudal, Telfast, Selsun, Dulcolax; (Serbia) Ibalgin, Bronchicum, Essentiale; (Switzerland) Nasobol; (Armenia) Finalgon, Magne B6, Festal, Enterogermina, Essentiale N, No Spa, Baralgin M, Guttalax, Pinosol, Lasolvan, Maalox, Essentiale Forte N; (Azerbaijan) Pinosol, Enterogermina, Bronchicum, Maalox, Ersefuryl, Libexin, Baralgin M, Mycoseptin, Essentiale Forte N, Buscopan, No Spa, Magne B6, Essentiale N, Finalgon, Festal, Lasolvan, Guttalax; (Belarus) Enterogermina, No Spa, Magne B6, Guttalax, Zodac, Essentiale, Lasolvan, Festal, Finalgon, Pinosol; (Georgia) Libexin, Lasolvan, Essentiale N, Vitamin E Sanofi, Enterogermina, Buscopan, Guttalax, Essentiale Forte N, Festal, Lifevit, Magne B6, Maalox, Finalgon, Mycoseptin, Pinosol, No Spa; (Kazakhstan) Festal, Propolki, Lasolvan, Anti Bit, Mycoseptin, Bronchicum, Finalgon, Dulcolax, Buscopan, Pinosol, Maalox, Magne B6, Vitamin E Sanofi, No Spa, Essentiale, Lasorin, Zodac, Enterogermina, Libexin; (Kyrgyzstan) Festal, No Spa, Guttalax, Essentiale N, Enterogermina, Finalgon, Essentiale Forte N, Magne B6, Pinosol, Lasolvan, Zodac; (Uzbekistan) Lasolvan, Essentiale Forte N, Libexin, Finalgon, Pinosol, Essentiale N, Maalox, Guttalax, Magne B6, Festal, No Spa, Zodac, Enterogermina.

Certain figures, including financial and market data, contained in this Presentation have been rounded and the relevant sums may not add up to 100 due to rounding.

Neither this Presentation nor the Information constitutes investment, legal, accounting, regulatory, taxation or other advice.

THIS PRESENTATION IS NOT AN INVITATION TO PURCHASE SECURITIES OF THE COMPANY OR THE GROUP.



30y
experience

Peter Goldschmidt

Chief Executive Officer

Joined in 2018

PREVIOUS EXPERIENCE



20y
experience

Boris Döbler

Chief Financial Officer

Joined in 2019

PREVIOUS EXPERIENCE



20y
experience

Ingo Schachel

Head of Investor Relations

Joined in 2024

PREVIOUS EXPERIENCE



H1 Highlights



STADA H1 2025: Fully on track for FY guidance after sustained outperformance in H1, Specialty outlook raised due to continued strong growth in Innovative and biosimilars



Key highlights in H1 2025

- 1** Growth¹ of **+6% in Adj. cc Revenues** with an attractive Adj. cc EBITDA² margin of 22.6%
- 2** **Outgrowing the market**^{3,4} in Specialty with 18% Adj. cc Revenues growth in H1 – FY segment revenue guidance increased
- 3** **CHC and Generics with MSD% growth in Q2** with strong contribution from launches
- 4** Adj. cc EBITDA: **Fully on track for FY guidance** (>50% of FY guidance mid-point delivered in H1)
- 5** **Over 50 new BD&L deals** signed in H1 2025 (thereof 41 in-licensing) with latest **Tocilizumab** biosimilar signed in August (€0.6bn EU originator sales)

Sources: Based on Company information; IQVIA sources, where indicated below

Notes: (1) Restated figures for 2024; (2) Adj. cc EBITDA refers to the Group's Adjusted EBITDA including additional foreign currency adjustments: first, the foreign exchange rates for the relevant financial year are applied to the comparator period; second, the realized and unrealized foreign exchange rate effects within the Group's Adjusted EBITDA are adjusted; (3) In STADA's Sx segment as of YTD March 2025; (4) IQVIA CH Customized Insights European Market Data, IQVIA MIDAS European Generics Market Data, IQVIA MIDAS European Specialty Market Data



Strong momentum in 2025 along our five strategic priorities: Minimal impact from US tariffs or regulatory changes; continued high pace of value-generating BD&L activities



Strong marketing and sales capabilities



- **Successfully launched** biosimilars/generics to several **blockbusters**, especially **Stelara** (Ustekinumab), **Xarelto** (Rivaroxaban) and **Pradaxa** (Dabigatran)
- **Minimal impact from US tariffs or weaker US consumer confidence** (<3% of revenues in the US, including royalties)



Portfolio acceleration via launches, BD&L and M&A



- **50 BD&L projects**, thereof 41 in-licensing deals signed in H1 2025
- **US ONAPGO launched** in April 2025 - strong initial interest from prescribers
- Preparation for launches of **Denosumab**, **Golimumab** (MAAs under review by EMA), **Tocilizumab** (signed in August 2025), and **Aflibercept** (MAA approved by EMA in August 2025)
- **Tocilizumab (bActemra)** signed in August 2025, launch expected in 2026
- Bolt-on CHC deals funded with value-accretive **divestment of Polytar**



Low-cost operating model



- Excellent **operational model with lean HQ and no silos**
- Modern and **scalable IT platform**, including ongoing preparation for S4Hana roll-out end of H1 2026
- **Fully invested SG&A infrastructure** with OPEX continuing to grow less than revenues growth
- Further **gross margin expansion in H1 2025** due to pricing and TechOps performance



Efficient and reliable supply chain



- **New packaging center in Romania** live and **ramping up** capacity utilization
- **Dual sourcing**, (70% of Top-50 APIs)
- **Reliable supply** while keeping **high service levels**



Growth culture




- **High employee engagement and satisfaction** based on semi-annual employee "Pulse" survey (May 2025 results: 86% participation, 87% confident STADA will achieve its business objectives)
- New international STADA **Health Report** published in Q2/2025 – unique 22-country survey in Europe with 27,000 participants

STADA with further accelerated growth in H1 2025 outpacing peers¹ in all segments



H1 Adj. cc Revenues^{2,3} (€m)

Growth (%)



- **Growth accelerated** with notable Q2 topline growth in CHC (+6%) and Generics (+4%) driven by recent launches
- **Continued strong growth** in Sx (Q2: +15%) with strong contribution from launches, e.g. Ustekinumab, Nilotinib, Paclitaxel
- **No meaningful impacts** from tariffs, US regulation changes, FX volatility

Sources: Based on Company information

Notes: (1) Calculated as outperformance versus the average peer sales growth in each of STADAs three segments; (2) Adjusted cc (constant currency) Revenues refers to Group's revenues adjusted using the relevant foreign exchange rates for the next following corresponding reporting period.; (3) Restated figures for 2024

Adj. cc EBITDA at a new record level in H1 2025 with pleasing double-digit growth in Specialty



H1 Adj. cc EBITDA^{1,2} (€m)

Adj. cc EBITDA Margin

22.6%

481

457

H1 2024

H1 2025

- **Continued 5%** Adj. cc. EBITDA growth in H1 2025, despite high prior year base (one-offs in H1 2024 results)
- FY Adj. cc EBITDA guidance reiterated with **more than 50% of the mid-point already generated in H1**
- **Solid Adj. cc EBITDA growth**, driven by gross margin expansion (pricing and good TechOps performance)
- Adj. cc EBITDA in H1 2025 **exceeds 50% of the mid-point of the FY guidance** range (€930m-€990m)

Sources: Based on Company information


Notes: (1) Adj. cc EBITDA refers to the Group's Adjusted EBITDA including additional foreign currency adjustments: first, the foreign exchange rates for the relevant financial year are applied to the comparator period; second, the realized and unrealized foreign exchange rate effects within the Group's Adjusted EBITDA are adjusted; (2) Restated figures for 2024

Consumer Healthcare unimpacted by US headwinds: Growth re-accelerated in Q2 2025 with outperformance vs. peers¹



Adj. cc Revenues² (€m)

Adj. cc EBITDA² (€m)



- **Excluding C&C/Seasonal Products**, Q1, Q2 and H1 Adj. cc Revenues grew by ~5%
- **H1 2024 comparison base** impacted by high sell-in of seasonal products³
- EBITDA **margin at a strong level** (despite less favorable product mix and higher M&S spending) to support launches


Sources: Based on Company information

Notes: (1) Calculated as outperformance versus the average peer sales growth in each of STADAs three segments; (2) Restated figures for 2024; (3) After Q1 revenues had been impacted by a double-digit decline of revenues with C&C and seasonal products


Generics: Solid MSD%¹ growth in Q2 fueled by strong launches and high exposure to the resilient & growing EU Generics market



Adj. cc Revenues² (€m)



Adj. cc EBITDA² (€m)



- **Adj. cc Revenues up +2% against high PY-base** (H1 2024 revenues impacted by positive one-time effects) with strong contribution of recent launches
- **Market share gains** across countries³ and **in-market sales growth of 6%**, well ahead of market growth rates
- **No exposure to the US generics market**, hence no impact from regulation changes or price pressure in the US


Sources: Based on Company information, and IQVIA source, where indicated below

Notes: (1) MSD = Mid-single-digit; (2) Restated figures for 2024; (3) Company data analysis referring to May 2025 YTD (Year-to-Date)


Specialty: Strong double-digit growth with excellent contribution of recent launches, e.g. Ustekinumab, Nilotinib, Paclitaxel & strong growth of Innovative medicines



Adj. cc Revenues¹ (€m)



Adj. cc EBITDA¹ (€m)



- Continued **strong revenue contribution of recent launches** in Specialty Generics and biosimilars, e.g. Ustekinumab, Nilotinib, Paclitaxel
- Broad-based **growth of in-market biosimilars**
- Increased patient uptake of **innovative medicines Kinpeygo and Lecigon** in multiple markets
- Strong Adj. cc EBITDA growth** despite build-up of M&S capabilities for upcoming launches
- Tocilizumab signed** in August 2025 (bActemra/bRoActemra) €0.6bn EU originator sales²)

Sources: Based on Company information

Notes: (1) Restated figures for 2024; (2) Originator sales in the year of LoE

STADA with accelerated and profitable organic revenues growth in Q2 – fully on track for 2025 guidance



Adj. cc H1 Revenues and Adj. cc EBITDA (€m)

	H1'25	%-Δ vs H1'24
Adj. cc Revenues	2,123	+6%
- organic growth		+6%
- M&A-effects		+0%
Adj. cc EBITDA	481	+5%
Adj. cc EBITDA margin	22.6%	-0.1 ppt
Currency gains/(losses)	-20	
Adj. EBITDA	461	+1%
Special item adjustments	3	
Reported EBITDA	458	+5%

Q2 Adj. cc Revenues growth of +7%¹ with:

- Growth firmly in MSD-HSD% growth corridor
- CHC growth of 6% and Gx growth of 4% with improvement vs Q1 and within the MSD% FY segment guidance range
- Fully organic
- Very limited FX effects (-0.2%)

H1 Adj. cc EBITDA growth of +5%, despite positive one-offs in H1 2024 EBITDA

Adj. gross margins improved due to segment mix (high-value Specialty products) and TechOps performance


M&S investment to fuel Sx and CHC (outside C&C) growth

G&A, excluding special item adjustments of €14m (SAP S4, exit-related and other one time costs), increased only +2% vs PY




Adj. cc EBITDA-evolution throughout the year: On track for FY'25 Guidance

Adj. cc EBITDA H1 vs H2 – actual results 2024¹



Adj. cc EBITDA H1 vs H2 split – usual pattern



Reminder: Half-yearly EBITDA-pattern 2024

- **H1 2024** unusually high based on strong seasonal sell-in and favorable one-time effects
- **H2 2024** unusually soft due to weak C&C and unfavorable one-time effects
- **H1 - H2 split** in 2024: c. 52% - 48%

Usually, H2 EBITDA > H1 EBITDA

- **H1 2025: Strong €481m adj. cc EBITDA** – representing >50% of mid-point of guidance (€960m)



H1 Adj. cc EBITDA €481m on track for FY '25-guidance of €930 to €990m

Fully on track for 2025 company guidance – Specialty growth guidance raised after strong and sustained H1 trend reflecting successful launch performance



Guidance: € or growth rate percentage ranges

2024 Results:

Adj. Revenues	€4,059m
• Consumer Healthcare	€1,537m
• Generics	€1,652m
• Specialty	€870m
Adj. cc EBITDA²	€886m

KPIs:

Adj. cc Revenues¹	~€4,250m to ~€4,400m <i>[unchanged vs. Feb'25]</i>
• Consumer Healthcare	Around mid-single-digits
• Generics	Around mid-single-digits
• Specialty	Low-double-digits <i>[Previously: High-single-digits to low-double-digits]</i>
Adj. cc EBITDA²	~€930m to ~€990m <i>[unchanged vs. Feb'25]</i>

2025 Forecast

Comment on range of outcome:

- **Swing factor C&C season** and SIT³
- H1 2025 C&C/Allergy revenues declined by LSD%
- H1 +2% - with **6% in-market growth⁴**
- Lower comps (esp. Germany) in H2 2025
- **Strong, sustained growth in H1 2025**, amongst other from of ustekinumab, Kinpeygo and in-market biosimilars, **prompts guidance hike**
- >50% of mid-point already generated in H1 (contrary to typical seasonal patterns)

Sources: Based on Company information

Notes: (1) Adjusted cc (constant currency) Revenues refers to Group's revenues adjusted using the relevant foreign exchange rates for the next following corresponding reporting period.; (2) Adj. cc EBITDA refers to the Group's Adjusted EBITDA including additional foreign currency adjustments: first, the foreign exchange rates for the relevant financial year are applied to the comparator period; second, the realized and unrealized foreign exchange rate effects within the Group's Adjusted EBITDA are adjusted; (3) Stock-in trade; (4) Company data analysis

STADA's mid-term guidance: Confident to deliver mid- to high single-digit topline and margin accretive Adj. cc. EBITDA growth; additional upside potential from M&A/BD&L



Guidance: € or growth rate percentage ranges

2024 Results	KPIs:	2025 Forecast (Q2-update)	Mid-term Guidance
Adj. Revenues €4,059m	Adj. cc Revenues²	~€4,250m to ~€4,400m	Mid to high single-digit
• Consumer Healthcare €1,537m	• Consumer Healthcare	Around mid-single-digits	Mid to high single-digit
• Generics €1,652m ¹	• Generics	Around mid-single-digits	Around mid-single-digits
• Specialty €870m	• Specialty	Low double-digits [Previously: High single-digits to low-double-digits]	High single-digits to low double-digits
Adj. cc EBITDA³ €886m	Adj. cc EBITDA³	~€930m to ~€990m	Growing faster than Revenues

Sources: Based on Company information

Notes: (1) 2024 revenues include €188m revenues from export of Azilsartan API + trading goods; (2) Adjusted cc (constant currency) Revenues refers to Group's revenues adjusted using the relevant foreign exchange rates for the next following corresponding reporting period.; (3) Adj. cc EBITDA refers to the Group's Adjusted EBITDA including additional foreign currency adjustments: first, the foreign exchange rates for the relevant financial year are applied to the comparator period; second, the realized and unrealized foreign exchange rate effects within the Group's Adjusted EBITDA are adjusted

Cash generative business model – H1 with temporary inventory increase related to strong Sx and Gx launches and bridging stock for strategic products

Core Free Cash Flow¹ (€m)


	H1'24	H1'25
Adj. cc EBITDA	100% 457	100% 481
Taxes ²	-36	-40
Change in NWC ³	-106	2 -199
Investments in PPE ⁴	-35	-26
Investments in IA ⁵	-58	3 -66
Proceeds ⁶	50	4 65
All other (incl. Reconciling items) ⁷	6	5 -49
Core Free Cash Flow	61% 278	34% 166 1

- 1 **Core Free Cash Flow** of €166m in H1 2025
- 2 **Changes in NWC 5%** of LTM⁸ revenues in H1 2025 due to temporary investment in inventories, a.o. for launches and bridging stock for strategic products - reduction expected in H2
- 3 **Investments in intangible assets⁵** to boost pipeline
- 4 **Disposal proceeds** of non-strategic brand (Polytar – competing with Nizoral) used to largely fund BD&L and bolt-on M&A investments
- 5 **'All other'** change vs H1 2024 mainly related to phasing of Health Insurance Rebate claims

Note: (1) Non-IFRS financial measure. Core Free Cash Flow refers to the Group's cash flow from operating activities from continuing operations plus payments for investments in property, plant and equipment, payments for intangible assets, financial assets and business combinations in accordance with IFRS 3 (excluding purchase price payments for single investments in M&A assets and BD&L assets exceeding €50 million, measured cumulatively over the lifetime of the asset), proceeds from the disposals of property, plant and equipment, intangible assets, financial assets and shares in consolidated companies as well as proceeds from government grants and proceeds and interest received or payments for loans granted; (2) Income tax paid and income tax received; (3) Change in NWC is defined as the changes in inventories and trade receivables less changes in trade payables; (4) Payments for investments in property, plant and equipment; (5) Payments for investments in intangible assets, financial assets and business combinations in accordance with IFRS 3 (excluding purchase price payments for single investments in M&A assets and BD&L assets exceeding €50 million); (6) proceeds from the disposals of property, plant and equipment, intangible assets, financial assets and shares in consolidated companies as well as proceeds from government grants and proceeds and interest received or payments for loans granted; (7) Includes currency effects and special item adjustments, interest received, dividends received, share of net profit of investments, result from the disposal of non-current assets, additions to/reversals of other non-current provisions, currency translation gains/losses, other non-cash income/expenses, changes in other net assets, unless attributable to investing or financing activities; (8) Last Twelve Months

Pro forma leverage of ~3x with ~€200m¹ of annual cash flow improvement from lower interest expense in the future

Illustrative pro-forma capital structure – June 30, 2025²



- Pro forma net financial debt **reduction by ~€3bn⁸** from ~€5.7bn to ~€2.7bn, repaying select debt instruments
- Net debt reduction financed using combination of **proceeds** and **shareholder equity contribution**
- Financial result⁵ in H2 2025 expected to be similar to H1 due to one-time effects relating to refinancing (including non-cash valuation effects on embedded options); post refinancing, **annual interest expense¹⁰ run-rate** will be <€150m
- FY 2025 interest expense expected to be ~€350m¹⁰ and transaction-related refinancing expenses of ~€50m and additional non-cash effects (e.g. embedded options valuation)
- Adj. net income in H1 2025 amounted to €85m based on the current interest rate. If interest expenses had already been at the future run-rate, Adj. net income for H1 2025 would have been ~€200m⁹

Source: Company information

Notes: (1) Based on illustrative interest rate savings of >€200m (~€360m minus €150m run-rate interest expenses, and taking into account that incremental interest expenses were not tax deductible); (2) Illustratively assuming no cash flow generation between June 2025 and the actual transaction date, capturing pro-forma adjustments before and shortly after the transaction, and repayment of select debt instruments in Q4 2025; (3) Nominal net financial debt / LTM H1 2025 Adj. cc EBITDA (€909m); (4) Net financial debt (defined as financial liabilities on a nominal basis, which therefore excludes leases, less cash and cash equivalents); (5) €325m in H1 2025 as displayed on slide 113; (6) Average interest rate (expected pro-forma run rate); (7) Expected indicative cost of new TLA debt issued under the new pro forma capital structure, approximated using a 3M EURIBOR of 2.0% and a illustrative margin of 2.5% or less (subject to confirmation); (8) Net proceeds to STADA after deducting transaction related refinancing expenses and accrued interest; (9) Based on €85m Adj. Net Income for H1 2025 plus illustrative interest expense run-rate savings of ~€200m (and taking into account that the incremental interest expenses were not tax deductible in H1 2025); (10) Net nominal interest expense to third-party lenders

Capital allocation framework



Organic growth investment

- **Opex** to support growth – under-proportionate to Revenues growth (operating leverage)
- **Net Working Capital** – inventory levels expected to increase slightly ahead of Revenues based on launches and segment-mix
- **Core Capex¹**, i.e. investments into property, plant and equipment, capitalized product development, payments under existing BD&L-deals as well as new BD&L-activity (<€50m cum. investment per deal)

Value-creating M&A / BD&L

- **M&A-deals** – predominantly in **Consumer Healthcare** – as per proven track-record, driving strong shareholder value within **1-3 years**
- **BD&L-deals** – predominantly in **Specialty** – as per proven track-record, driving strong shareholder value within **3-5 years**



Leverage target

- STADA is aiming to **de-lever** to ~3x Net Financial Debt /Adj. cc EBITDA at-transaction and towards **~2.5x in the mid-term**
- **Reduction of interest burden post-transaction** through debt refinancing in April and June 2025 and at-transaction repayment and refinancing of debt

Dividend policy

- STADA's dividend policy foresees a payout ratio of **>30% of reported Net Income²** and would strive to **pay a dividend of €25m for 2025 payable in 2026**

Source: Company information




Note: (1) Core Capital Expenditures is defined as the payments for investments in intangible assets, property, plant and equipment, financial assets, as well as business combinations in accordance with IFRS 3 (excluding purchase price payments for single investments in M&A assets and BD&L assets exceeding €50 million, measured cumulatively over the lifetime of the asset). Core Capital Expenditures also include proceeds from the disposal of intangible assets, property, plant and equipment, financial assets, shares in consolidated companies and proceeds from government grants; (2) Based on reported Net Income attributable to shareholders and subject to ability to distribute based on relevant legal entity local GAAP-results

STADA – people, portfolio & pipeline for continued growth



STADA's management team has a strong success track record across all segments



Name & Position ¹	Experience			Sector expertise		
	Consumer Healthcare	Generics	Specialty			
 Peter Goldschmidt Chief Executive Officer				<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
 Boris Döbler Chief Financial Officer		 		<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
 Simone Berger Chief People Officer		 		<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
 Miguel Pagan Chief Technical Officer				<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
 Volker Sydow Global Consumer Healthcare				<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
 Bryan Kim Western Europe				<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
 Ian Henshaw Global Specialty		  		<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
 Yann Brun Global Dev, Portfolio, Reg, BD&L		 		<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
 Martin Hess Head of Global Sustainability				<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
 Christos Gallis Eastern Europe		 		<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
 Stéphane Jacqmin Emerging Markets		 		<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
 Felix von Berg Global M&A		 		<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
 Christoph Dengler General Counsel				<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
 Frank Staud Global Communications		 		<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>






Source: Company information

Note: (1) EVP Germany to be announced in Q4 2025; (2) Current Chairman of the Supervisory Board;

STADA has a rich launch pipeline across all segments for 2026 and beyond



2026+

<p>Innovative</p>	<p>Strong funnel of 185 deals being screened</p>		
<p>Biosimilars</p>	 		 
<p>Specialty Generics (examples)</p>	<p>Ruxolitinib <small>JAKAVI</small></p> <p>GLP-1s (Obesity) <small>wegovy Saxenda</small></p>	<p>Ivacaftor <small>kalydeco</small></p>	<p>Enzalutamide <small>Xtandi</small></p>
<p>Generics (examples)</p>	<p>Edoxaban <small>Lixiana</small></p> <p>GLP-1s (Diabetes) <small>OZEMPIC VICTOZA</small></p>	<p>Apixaban <small>Eliquis</small></p>	<p>Empagliflozin <small>Jardiance</small></p>
<p>Consumer Healthcare (examples)</p>	<p>Strong innovation & launch pipeline building on 242 Local Hero & >130 Sleeping Beauty brands and a leading rank on the Innovation Freshness Index (9.2%³)</p>		



- **50 new BD&L deals** signed in H1 2025 (thereof 41 in-licensing)
- **>260 projects under development** (thereof >150 internal product developments)
- **Five new biosimilars** to be launched in 2026 (total originator sales: €2.8bn¹)
- Strong deal funnel of **Innovative in-licensing opportunities**
- **Historical and target LoE coverage of ~85%²** in Generics with strong first-to-market launch capabilities (~80% in first wave)

Source: Company information, Company Data Analysis

Note: (1) Originator sales in the year of LoE; (2) Average historical LoE coverage between 2019-2024 as well as the expected coverage from 2025-2028; (3) Percentage of MAT sales generated by the last three years' launches from the total MAT sales in March 2025, STADA ranks #7 among the top-7 EU CHC companies



Key financial & value creation highlights – Extending our track record of outperformance in H1 2025 and FY 2025 & tapping additional value creation potential

2021-24

- Strong **track record of outperforming European markets¹** in all three segments
- Demonstrated growth in attractive **Specialty niches and biosimilars**
- **Fastest-growing major OTC-company** in Europe (in 2022-24)

H1 2025

- Another **half-year with strong outperformance vs. peers²**
- Well **on track for FY guidance with >50% Adj. cc EBITDA** in H1
- CHC and Gx segments with Adj. cc Revenue growth acceleration in Q2 2025

FY 2025

- **Segment growth guidance upgrade for Specialty** due to sustained strong growth, esp. in **biosimilars and Innovative** medicines
- Guidance for CHC implies continued clear outperformance vs. peers

Value Creation Highlights

2 bolt-on acquisitions in CHC

In H1 2025, financed with the value-accretive divestment of Polytar

50 new BD&L deals

In H1 2025, thereof 41 in-licensing

Tocilizumab signed

bActemra, launch expected in 2026, €0.6bn EU originator sales³

Deal funnel of 185

products under evaluation in Innovative






>260

Development projects

Source: Company information

Note: (1) Refers to Dec-2021 to Dec-2024 CAGR for STADA based on Company data analysis and Dec-2021 to Dec-2024 CAGR for market based on IQVIA CH Customized Insights European Market Data FY & IQVIA MIDAS European Generics Market Data & IQVIA MIDAS European Specialty Market Data; (2) Calculated as outperformance versus the average peer sales growth in each of STADAs three segments; (3) Originator sales in the year of LoE

STADA – A distinctive investment case in Healthcare

- 1 Focused on **large, mostly non-cyclical markets** growing **mid-single to low-double-digit**
- 2 **Track-record of outperforming** relevant markets¹ with leading positioning and attractive risk profile
- 3 **Differentiated strategy** for Consumer Healthcare, Generics and Specialty – with symbiotic nature of the three segments
- 4 **Strategic pillars** for long-term **market outperformance in top- and bottom-line**
 -  Strong **marketing** and **sales** capabilities
 -  Portfolio acceleration via **launches, BD&L** and **M&A**
 -  **Low-cost** operating model
 -  Efficient and reliable **supply chain**
 -  **Growth Culture** – strong performing teams, growth mindset & ESG
- 5 **Strong Revenues growth, Adj. EBITDA margin expansion** and **Cash flow generation** with **value-accretive M&A / BD&L** track record and pipeline

STADA – A distinctive investment case in Healthcare

General introduction for investors





STADA

A leading supplier of healthcare products across Self-Care (Consumer Healthcare), Primary Care (Generics) and Specialty Care (Specialty), fully integrated across global product development, procurement and manufacturing, and commercialization


STADA – A leading supplier of Healthcare¹ products




Key financials 2024

Revenues	€4.1bn +9% vs. 2023
Adj. EBITDA⁷	€0.9bn +11% vs. 2023
Adj. EBITDA margin⁷	22%


Revenues by segment²



Revenues by product^{2,3,4}



Revenues by country^{2,3,5}



Key statistics

<p>No. 4 player in Consumer Healthcare⁹ and Generics¹⁰ across Europe</p> <p>>260 development projects¹³</p>	<p>>200 Consumer Healthcare brands¹¹ with leading (rank 1-3) position in their respective disease categories in their respective countries</p> <p>6 Biosimilars¹⁴ and 4 Innovative¹⁵ treatments in the market with strong pipeline of upcoming launches</p>	<p>Fastest-growing major OTC-company in Europe¹² in 2022-24¹²</p> <p>16¹⁶ manufacturing sites in 11 countries mainly in low-cost locations; ensuring supply reliability</p>
---	---	--

Source: Company information, IQVIA, where indicated below



Note: (1) Consumer Healthcare, Generics and Specialty markets; (2) 2024 Revenues; (3) Based on Company's internal management reporting system or accounting records, unaudited and not reviewed by auditors; (4) Revenues by Product with product defined as combination of SKUs using the same API (Active Pharmaceutical Ingredient) or brand name and assigned to same "Profit Center" as per SAP Management Reporting system; (5) Revenues by country based on customer billing address; (6) ROW includes among other revenues with Russia as this purely relates to Contract Manufacturing Organization ("CMO") business as well as API sales into the US; (7) Key alternative performance measure, eliminating items which are not relevant to the ordinary course of business operations from EBITDA, to be able to show the underlying operational and financial performance; (8) International Non-proprietary Name ("INN"). INN generics are generic drugs marketed and sold using only the generic chemical name and are not given a brand name; (9) Based on IQVIA CH Customized Insights European Market Data for the calendar year 2024; (10) Based on IQVIA MIDAS European Generics Market Data for calendar year 2024 (11) CHC Local Hero Brands; (12) Based on IQVIA CH Customized Insights European Market Data for CAGR 2022-2024 ; (13) Including more than 150 internal product developments; (14) Excluding Pegfilgrastim with minor sales in Germany only until April 2025 (contract terminated in December 2024); (15) Apo-Go®, Kinpeygo®, Lecigon®, Corpos®; (16) Current count of 16 manufacturing sites excludes Pfaffenhofen, which was closed on Dec 31, 2024; (17) Of which >70% in EU27 and UK. Europe includes EU27, UK, Switzerland, Norway, Balkans, Ukraine, Israel, and Eurasia



Since 2017, significant transformation of a ~130 year heritage company into a leading supplier of Healthcare¹ products

Revenues (€bn)

Adj. EBITDA (€bn)




STADA's history



Source: Company information
 Note: (1) Consumer Healthcare, Generics and Specialty markets; (2) Business Development & Licensing

All three segments with strong topline and adj. EBITDA growth over the years and strong profitability of ~25% in CHC, ~24% in Gx and ~33% in Sx




Source: Company information

Note: (1) Revenues adjusted by the inorganic portion of Revenues growth. The inorganic growth is defined as the first twelve-month Revenues contribution from a merger or acquisition or an asset deal, effective as of the closing date. For any periods after the initial 12-month period, only the portion of the Revenues generated by the relevant entity or product that exceeds the first 12-month revenues will be regarded as organic and considered for the calculation of organic growth. Organic growth calculations are adjusted for divestments as divested assets no longer contribute to growth; (2) Segment Adjusted EBITDA margin excludes central costs; (3) Negative FX impact on 2024 EBITDA of €12m



Strong organic growth driven by volume and product launches in all three segments, Consumer Healthcare with highest price increases and inorganic growth¹



Illustrative impact

Impact Category	Consumer Healthcare	Generics	Specialty
Volume²	<p>Volume growth driven by local brand activation; help from Covid suppressed base in 2021 mitigated by soft C&C in '24</p>	<p>Volume growth driven by existing molecules and market share gains</p>	<p>Biosimilars (incl. EPO drug substance supply to US) growth and Lecigon ramp-up</p>
Price³	<p>Price adjustments driven by low price elasticity and pass-through of '22-'23 inflation</p>	<p>Price erosion largely mitigated by "Gross-to-Net" optimization (sales deductions)</p>	<p>Price erosion largely driven by normalizing pricing levels for Bortezomib</p>
Product launches	<p>Successful line extensions of Local Hero brands</p>	<p>Continuous launches at LoE of originators (incl. Rivaroxaban, and Dabigatran in 2024) as well as successful launches at risk</p>	<p>Biosimilar (incl. Ustekinumab which was launched in 2024), Lecigon and Kinpeygo roll-out in several markets</p>



Inorganic CAGR contribution

- Consumer Healthcare:** Impact of 3%pts on CAGR from acquisitions between 21 and 24
- Generics:** No significant inorganic impact on Generics
- Specialty:** No significant inorganic impact on Specialty⁴

Source: Company information
 Note: (1) Inorganic growth is defined as the first twelve-month Revenues contribution from a merger or acquisition or an asset deal, effective as of the closing date. For any periods after the initial 12-month period, only the portion of the Revenues generated by the relevant entity or product that exceeds the first 12-month Revenues will be regarded as organic and considered for the calculation of organic growth. Organic growth calculations are adjusted for divestments as divested assets no longer contribute to growth; (2) Volume growth of existing business; (3) Net selling price development; (4) Lobsor / Lecigon acquisition in 2020; as per above-described inorganic definition, the strong growth from roll-outs as of month 13 is counted under organic / product launches

STADA's resilience based on diversification and manufacturing footprint




Diversification of Segments and Products

2024 Revenues by product^{1,2}

Top 10 Specialty products
(Total Sx share: 21%)

Top 10 Consumer Healthcare products
(Total CHC share: 38%)

Largest product accounts for <4% of Revenues



Top 10 Generics products
(Total Gx share: 41%)

- Diversified product portfolio with >1,000 products within CHC, >600 products in Gx and >300 products in Sx as of 31-Dec-24
- Balanced portfolio with the largest product making up less than 4% of Revenues

Broad Based Manufacturing Capacity to Ensure Supply Reliability


Overview of STADA's 16 manufacturing sites

Country	Site
Germany	Bad Vilbel Uetersen Pfaffenhofen ⁶
UK	Huddersfield Preston
Austria	Tulln
Serbia	Vrsac PC ⁴ Sabac Vrsac/Dubovac
Vietnam	Tuy Hoa PME 1 Tuy Hoa PME 2
Czechia	Trinec
Montenegro	Podgorica
China	Miyun
Ukraine	Bila Tserkva
Romania	Turda PC ^{4,5}
Bosnia and Herzegovina	Banja Luka

- Diversified manufacturing footprint with 16 sites across 11 countries in Europe and Asia
- ~70% of top 50 APIs dual sourced to support supply reliability as of 31-Dec-24
- Broad CMO network ensuring reliable and flexible supply

Well-positioned regarding US Tariff Challenges

2024 Revenues by geography^{1,3}



- Strong and diversified presence across Western Europe and Eastern Europe (>85%)
- Apart from Germany, no single country concentration
- Low US exposure with only <3% of Revenues and hence low tariff risk

Source: Company information

Note: (1) Based on Company's internal management reporting system or accounting records, unaudited and not reviewed by auditors; (2) Revenues by Product with product defined as combination of SKUs using the same API (Active Pharmaceutical ingredient) or brand name and assigned to same "Profit Center" as per SAP Management Reporting system; (3) Revenues by country based on customer billing address; (4) Only packaging; (5) Starting operations in Q4 2024; (6) Cease operations 31st December 2024; (7) ROW includes among other revenues with Russia as this purely relates to Contract Manufacturing Organization ("CMO") business as well as API sales into the US; (8) Of which >70% in EU27 and UK. Europe includes EU27, UK, Switzerland, Norway, Balkans, Ukraine, Israel, and Eurasia


Focused on large, growing and mostly non-cyclical European Healthcare markets



Consumer Healthcare Market

European Consumer Healthcare market, EUR bn gross sales

○ CAGR




Growth Drivers

- Ageing population
- Increasing market penetration
- Increasing shift to self care and prevention
- Premiumization and innovation driving pricing

Generics Market

European Generics market, EUR bn gross sales

○ CAGR




Growth Drivers

- Ageing population
- Generic penetration in most European countries still low & growing
- 2025+ looming patent cliffs and regulatory tailwind
- Increased value of upcoming LoEs¹

Specialty Market

European Specialty market, EUR bn gross sales

○ CAGR



Growth Drivers

- Prescription drug spending on chronic diseases
- Increasing market penetration across Europe
- Large value of upcoming LoEs of Biologic and Specialty-Generic medicines²

Sources: Historical and forecasted market data in terms of gross sales for the CHC, Gx and Sx markets based on Company Data Analysis


Note: (1) Loss of patent-protected exclusivity of originator drugs. Refers to value of INN-Generics LoEs in terms of originator gross sales the year prior to loss of exclusivity based on IQVIA data; (2) Refers to value of Biologic and Specialty-Generics LoEs in terms of originator gross sales the year prior to loss of exclusivity, based on IQVIA MIDAS European Market Data

Consistently outperformed relevant European markets driven by strong organic growth




Consumer Healthcare (38%¹)

The fastest-growing major Consumer Healthcare company in Europe between 2022-2024², covering all main consumer health categories with a broad portfolio of Local Hero brands³




Generics (41%¹)

A leading Generics player offering affordable medication in all essential categories in attractive European, Eurasia and Emerging Markets



Specialty (21%¹)

Attractive portfolio of Biosimilars, Specialty Generics and Innovative Treatments with more than 15 years of experience in biosimilars and a strong launch track record



Sources: Based on Company information; IQVIA sources (for full calendar year, except where indicated otherwise), where indicated below; M&A ranking based on Biomedtracker;

Note: (1) As % of 2024 Revenues; (2) Based on IQVIA CH Customized Insights European Market Data for 2022-2024; (3) Local Hero brands: brand obtaining top 3 position (in terms of market gross sales) in a given country in Consumer Healthcare tier three category; Consumer Healthcare tier three is a more granular class assigned to the more general classes; (4) Refers to Dec-2021 to Dec-2024 CAGR for STADA based on Company data analysis and Dec-2021 to Dec-2024 CAGR for market based on IQVIA CH Customized Insights European Market Data FY & IQVIA MIDAS European Generics Market Data & IQVIA MIDAS European Specialty Market Data; (5) Revenues adjusted by the inorganic portion of Revenues growth. The inorganic growth is defined as the first twelve-month Revenues contribution from a merger or acquisition or an asset deal, effective as of the closing date. For any periods after the initial 12-month period, only the portion of the Revenues generated by the relevant entity or product that exceeds the first 12-month revenues will be regarded as organic and considered for the calculation of organic growth. Organic growth calculations are adjusted for divestments as divested assets no longer contribute to growth; (6) IQVIA CH Customized Insights calendar year 2019 data, LEU MNF, (released Q1 2020 with same country scope as IQVIA CH Customized Insights European Market Data; (7) IQVIA CH Customized Insights European Market Data FY for calendar year 2024; (8) IQVIA MIDAS European Generics Market Data for calendar year 2024; (9) IQVIA MIDAS European Specialty Market Data for calendar year 2024

Three distinct strategies to differentiate STADA in each segment



Consumer Healthcare

- Driving portfolio of **Local Hero brands**¹ across OTC categories and STADA geographies
- Playbook of **brand-activation**, brand strengthening, and **brand-stretching** fueled by **innovation** (line extensions)
- Tailor-made Go-to-Market ("GTM") model with **strong pharmacy-channel capabilities**, supplemented by **e-commerce and digital competencies**



Generics

- **Deliberate geographic footprint** (e.g. no USA) with highly **localized country-specific GTM** approach based on deep understanding of each market
- Speed to market ("**First-in**") and cost leadership ("**Last-out**")
- **Large portfolio** and **reliable supply**
- **Strong regulatory competence and pipeline** with **LoE coverage ~85%**²: securing all economically viable launches



Specialty


- Build and grow portfolio with **complex, high growth & high margin Specialty products**
- **Innovative Specialty in niche / orphan space** with mid-range peak Revenues (€50-150m)
- RoI-based **selective Biosimilars** portfolio and pipeline
- Be **partner of choice** for Specialty in-licensing

STADA's Strategy






Our performance is based on a clear strategic framework with Growth Culture at its core



STADA: Strong commercial focus on Europe and selected Emerging Markets



Commercial focus:





All three segments have a highly complementary financial profile

Consumer Healthcare

Generics

Specialty

<p>1 Product lifecycle</p>	<p>Continued financial investments in long term brand building</p>	<p>Peak Revenues in first year</p>	<p>Peak Revenues in 5 to 10 years</p>
<p>2 Cyclicalty</p>	<p>Limited cyclicalty</p>	<p>Very limited cyclicalty / recession-proof</p>	
<p>3 Pricing</p>	<p>Largely free pricing</p>	<p>Pricing largely regulated</p>	
<p>4 Capex requirements</p>	<p>M&A opportunities</p>	<p>Limited capex needs, high cash generation</p>	<p>Growth opportunities from BD&L-capex</p>

STADA realizes symbiotic effects across the segments and along the entire value chain




Synergy area

Consumer Healthcare


Generics

Specialty





Source: Company information
 Note: (1) Active Pharmaceutical Ingredient

STADA's portfolio of Local Hero brands¹ provides a flexible growth platform



STADA's Local Hero¹ brands³



Sources: Based on CHC Local Hero Brands; Company Data Analysis


Note: (1) CHC Local Hero Brands data is as of December 2024; (2) Includes brand of STADA - Sanofi Commercialization Agreements in Europe and Eurasia; Under the Sanofi Commercialization Agreements concluded in November 2021 and April 2023, comprising 34 local brands and 8 global brands, STADA takes full responsibility for the entire commercialization value chain (distribution, promotion, regulatory, pharmacovigilance and medical services); (3) Number of Local Hero brands; (4) Including Italy, Spain, Switzerland, Finland, Lithuania, Netherlands, France, Latvia, Poland, Georgia, Estonia, Norway, Sweden, Croatia, Portugal and Slovenia



STADA is leading in terms of market share gains in European market


2019:
STADA #10 in the market with 1.7% market share¹

European market share by gross sales (2019)




2023:
STADA #4 in the market with 2.9% market share¹

European market share by gross sales (2023) Market share vs. Dec'19 in p.p.



2024:
STADA #4 in the market with 2.9% market share¹

European market share by gross sales (2024) Market share vs. Dec'19 in p.p.



Sources: Based on STADA; IQVIA sources, as indicated below


Note: (1) IQVIA CH Customized Insights European Market Data FY for calendar year 2023 and 2024; IQVIA CH Customized Insights data calendar year 2019 data, LEU MNF, (released Q1 2020) (same country scope as 2023 and 2024 data) which does not capture full market (e.g., online channel) hence market share multiplied by market size not resulting in true STADA gross sales - methodology consistent across years. Glaxosmithkline has been renamed to Haleon, Johnson & Johnson has been renamed to Kenvue

STADA is ranking #1 Innovation Freshness Index¹, ahead of all key competitors²



Innovation Freshness Index¹

% MAT Sales generated by last three years launches from the total MAT sales in March 2025



Key Drivers


- **Innovation pipeline is fueled by** internal / external development & licensing, particularly via the scalability of its large **Local Hero brands³** across OTC categories and STADA geographies
- Localised **decision-making framework and agility** allows rapid adoption **to local customer needs**

Source: Based on Company information; IQVIA sources, where indicated below

Note (1) Based on IQVIA CH Customized Insights European Market Data for MAT March 2025, IQVIA Freshness index is the % of Sales accounted for by innovation (New Products + Line Extensions); (2) Top-7 competitors by MAT March 2025 in Europe;

(3) CHC Local Hero Brands

Accelerating growth via e-Commerce in profitable high growth markets



STADA's e-Com acceleration playbook

- 1** Focus e-Com efforts on **countries with substantial e-Com size already** and future growth potential







- 2** Concentrate on **e-Com suitable categories like VMS & Derma** (given planned purchase characteristic)
- 3** Ensure **utmost consumer centricity** in low brand loyalty environment (e.g. Daosin big-pack focus in Germany, Eunova B12 in CBEC China)
- 4** Build **local & pan-European relationships with leading e-Com players** (e.g., Amazon, Redcare Pharmacy)
- 5** Make **data-driven, RoI-focused decisions** utilizing the power and expertise of dedicated **cross-departmental digital teams** and **continuous upskilling of employees** (e.g., Digital Academy)

E-commerce growth in Germany & China: A growth engine for STADA Consumer Healthcare




Germany eCommerce Revenues Development

- e-Commerce **revenues CAGR of +21%¹** from 2021 to 2024
- Growth mainly driven by Grippostad, Elotrans and Nizoral** as well as focus on **strategic growth partners** (Amazon & Redcare Pharmacy)



China eCommerce Revenues Development


- e-Commerce **revenues CAGR of +79%¹** from 2021 to 2024
- Growth mainly driven by** three key brands: **Eunova** (vitamins), **Viscontour** (cosmetics), **Hoggar** (sleeping aids)




STADA is one of the fastest growing global CHC companies



2024:
Top 10 global CHC players - Market share by value¹



2024:
Top 10 global CHC players – Gross sales growth by value vs PY¹



Source: IQVIA Global OTC Insights, for the time period MAT Q4 2024, reflecting estimates of real world activity (includes estimates of e Commerce & Mass market; excludes Venezuela)

Notes: (1) Gross sales as defined by IQVIA, different to Revenues as defined by the company

Transforming brands is a key growth driver for STADA Consumer Healthcare



Selected brand highlights

Nizoral®

Doubled revenues since acquisition through innovation & roll out



↑ x2
Revenues 2021-24¹



- #1² medicated anti dandruff
- Roll out, now 26 countries
- Adding Daily, Cream, Scalp

Zoflora

From disinfection concentrate to a successful household brand



↑ 7%
Revenues CAGR 2021-24¹



- #1² homecare disinfectant UK
- Expansion to MEA
- Adding trigger spray, floor wipes, carpet foam, toilet cleaner

ELOTRANS®

From diarrhea medicine to popular electrolyte brand



↑ x4
Revenues 2021-24¹






- Fast growing electrolyte
- From Germany to 9 countries
- Targeting a broader range of consumers, from athletes to individuals, requiring rehydration

Source: Based on Company information, Company Data Analysis, IQVIA sources where indicated
 Notes: (1) Based on Company's internal management reporting system or accounting records, unaudited and not reviewed by auditors. Revenues by country based on customer billing address; (2) Based on IQVIA CH Customized Insights European Market Data for MAT as of March 2025, additional countries Saudi and UAE, CHC3 category 86B1; (3) Company Data Analysis, market position within specific product category in UK; (4) Based on IQVIA CH Customized Insights monthly sales value data (LEU MNF) for Germany for MAT as of March 2025, CHC3 category 03D3

The European market is a fundamentally more attractive market than the US market



Characteristics of the EU & US Market

	 Characteristics of the EU Generics market	 Characteristics of the US Generics market
Market access & regulatory	<div style="display: flex; align-items: center; justify-content: center;"> <div style="border: 1px solid blue; border-radius: 15px; padding: 5px; text-align: center; width: 150px;"> EMA <i>Central regulatory authority</i> </div> <div style="font-size: 2em; margin: 0 10px;">+</div> <div style="border: 1px solid blue; border-radius: 15px; padding: 5px; text-align: center; width: 150px;"> >30 <i>Local regulatory agencies</i> </div> </div>	<div style="border: 1px solid gray; border-radius: 15px; padding: 5px; text-align: center; width: 150px;"> FDA <i>Single regulatory entity</i> </div>
Market structure & dynamics	<i>Complex market structure driven by operating in multiple countries and across fragmented customer base</i>	<i>Buyer oligopoly (payors/PBMs/pharmacy chains)</i>
Pricing and Gx dynamics	<p><i>Strong price resilience across markets</i></p> <p><i>Gx uptake varies by market archetype but slower than US</i></p> <p><i>No major on-going litigations. Good reputational profile</i></p>	<p><i>Higher originator prices compared to EU</i></p> <p><i>Rapid price drop post launches & market price deterioration</i></p> <p><i>Several litigations still on-going. Negative reputational profile</i></p>
Overall attractiveness		Low

STADA has distinct strategic differentiators vs. all competitor archetypes

Strategic differentiators of STADA vs. competitor clusters


	STADA	Global players	Regional champions	Local champions	Indian players
Local market insights and presence	✓	≈	✓	✓	✗
Pan-European scale	✓	✓	≈	✗	≈
Symbiotic CHC offering	✓	✗	✗	≈	✗
Localized GTM	✓	≈	✓	✓	✗
	Only player combining pan-European scale with localized presence and a synergistic CHC offering	Competitive scale and cost base, but HQ-driven and unable to derive synergies with CHC	Mostly not reaching truly pan-European scale, often focused on subregions (particularly in Eastern Europe)	Strong profile limited to respective home market, neither desire nor capabilities to expand beyond	Strong cost competitiveness, scale, and Gx focus, but often lacking local market know-how and presence

Tailored business model

- **Strong commercial platform** based on highly tailored GTM models and **excellent local commercial execution**
- Total of **>3,000 FTE¹ in commercial functions**, thereof >2,000¹ internal sales force FTE + >190¹ external FTEs. Other functions comprise marketing, customer service, and sales back-office FTE
- **Strong marketing and sales capabilities** with highly effective salesforce
- **Low-cost operating model** drives cost competitiveness
- **Reliable supply chain** critical for supply reliability
- **Portfolio acceleration** through breadth across TAs and launch effectiveness

STADA's market opportunity is set to expand on the back of blockbuster LoEs

Value of non-Specialty LoEs¹ in Europe (originator gross sales, €bn)



Highlights

- **Full visibility on LoE pipeline** based on originator drugs' **patent protection** timeline, allowing Generics players to plan ahead
- More drugs lose patent protection at higher **avg. value**, leading to **>2x higher** LoE value p.a. '25E-'28E vs. '19-'24 (e.g., Apixaban)

Examples of upcoming major LoEs:



Source: Company Data Analysis; based on certain assumptions, actual results may deviate materially from forecasts. For more information on projections and other forward-looking information please see the section titled "Important Information".


Note: (1) Does not include originator drugs classified as specialty or biologics



STADA has a strong track record of first-to-market launches with potential for further growth with broad coverage of future LoEs

STADA's robust launch performance

Market value coverage for top 20 LoE launches in Europe 2022-2024 with presence of at least 1 top 4 player




Strong coverage and launch capabilities

- **Average historical LoE coverage of >85%** between 2019-2024 demonstrating STADA's **industry leading portfolio management capabilities**
- Solid **first to market launch capabilities** covering **~80% of LoE market value** of top twenty LoE launches in Europe between 2022-2024, driven by **continuous strategic enhancement** (incl. dual development strategy)
- Strong **internal development** capabilities and established network of **strong partners**
- Significant **value creation potential** going forward: Maintaining strong **LoE coverage of ~85%** during upcoming wave of LoEs, **IP strategy** designed to enable first to market launches, leverage **own packaging** plant in Romania
- **Strategic co-development partnerships** to access a vertically integrated value chain for further portfolio expansion



STADA Specialty portfolio is well balanced with high-growth and high stability

STADA Specialty Revenues (including product category split for 2024) (€m)



Description of product categories

Innovative

Drugs w/ **market exclusivity** addressing unmet clinical needs. STADA focuses on indications with **concentrated patient/prescriber base** and mid-range Revenues potential

Biosimilars

Off-patent **large molecules** (e.g., monoclonal antibodies) with **clinically proven bio-similarity** to originator product and marketed under Biosimilars regulatory pathway

Specialty Gx¹ (incl. Branded Gx)

Off-patent small-molecule prescription medications for **chronic, complex, or rare diseases** and well-established products with **distinct brand heritage and customer loyalty**





Source: Company information

Note: (1) According to IQVIA, to qualify as specialty generics, prescription drugs must meet at least four of the following seven criteria: (i) high annual costs, (ii) initiated and maintained by a specialist drug therapy, (iii) practitioner administered, (iv) special procedure required (refrigerated, frozen, other biohazard), (v) reimbursement assistance required, (vi) limited distribution and (vii) extensive monitoring or comprehensive patient counselling required; (2) 2021-2024 CAGR



Movymia® (Teriparatide) and Oyavas® (Bevacizumab) have taken significant market share showcasing the strength and breadth of STADA biosimilars



#1 market position based on **strong established prescriber field force** and dedicated **home care support**




Strong performance through **leveraging existing Generics hospital infrastructure** and **tender teams**

Source: Based on IQVIA MIDAS European Specialty Market Data for calendar years 2019 to 2024 molecules TERIPARATIDE and BEVACIZUMAB

Steady stream of high-value biologic LoEs is on the horizon and STADA is well positioned as partner of choice for biosimilars

Biosimilar LoE Pipeline

LoE value incl. STADA's coverage (€bn)¹



STADA pipeline status²

STADA pipeline status ²	Total LoE value
■ Signed	€2.8bn
■ In advanced discussions	€24.5bn
■ Assessment ongoing	€19.3bn
■ Deprioritized	€1.4bn

Comments

- **STADA proactively monitors upcoming Biologics LoEs** and assesses opportunities to license and launch Biosimilars
- **Significant value accretive upside potential (not yet included in mid-term guidance)** from additional in-licensing opportunities under advanced discussions
- STADA's signed biosimilar pipeline covers below major LOEs:
 - **Actemra (Tocilizumab)** expands STADA's autoimmune portfolio, leveraging existing rheumatology infrastructure
 - **Prolia & Xgeva (Denosumab)** with synergies to STADA's bone health and oncology portfolio
 - **Simponi (Golimumab)** with synergies to marketed immunology biosimilars
- **Eylea (Aflibercept)** with synergies to in-market biosimilar - Ranibizumab (rights to market in Germany)

Source: Company Data Analysis (based on certain assumptions, actual results may deviate materially from forecasts; for more information on projections and other forward-looking information please see the section titled "Important Information")


Note: (1) LoEs & Market value based on Company Data Analysis (European markets inc. Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK), actual IP status could differ affecting the launch timeline of any assets; (2) Pipeline status assessment as of August 2025

STADA covers the majority of expanding specialty generics LoEs with strong partners



Specialty Generics LoE Pipeline¹

LoE value incl. STADA's coverage (€bn)



STADA pipeline status²

STADA pipeline status ²	Total LoE value
■ Signed/in pipeline	€21.9bn
■ Assessment/discussion ongoing	€16.0bn
■ Deprioritized	€0.2bn

Comments

- **Strong track record** of first-to-market launches based on development, BD&L, and regulatory capabilities (e.g., pro-active IP challenge)
- **Full visibility of the pipeline** (across general Generics and Specialty Generics) and proactive evaluation of internal development options as well as BD&L network
- **Strategic partnerships to access a fully integrated value chain** for portfolio expansion
- **Examples of major blockbusters / LoE covered in STADA's pipeline:**
 - Kalydeco (Ivacaftor) from Vertex
 - Xtandi (Enzalutamide) from Astellas
 - Ibrance (Palbociclib) from Pfizer
 - Various protein kinase inhibitors including Imbruvica (Ibrutinib) and Jakafi (Ruxolitinib)


Strong deal funnel of Innovative Specialty in-licensing opportunities for the near future



Deal funnel (n=185)

Number of products under evaluation split by therapeutic areas and stage of development

Others Nephrology Neurology




Comments

- Enhance the product pipeline via **BD&L**
- Concentrate on **orphan areas** and **niche specialty pharmaceuticals**
- Expand the pipeline with **Phase II/III** assets noted for **high unmet medical needs** and a **limited prescriber base**
- Aim to introduce comparable products like Lecigon and Kinpeygo, targeting peak sales of **€50-150m**
- **Structured approach** to guarantee high-quality, attractive deals from a scientific, medical, and financial standpoint

Appendix Consumer Health



STADA – The fastest-growing Consumer Healthcare Business in Europe (2022-2024)¹, driven by specific Go-To-Market approach




Sources: Based on Company information, Company Data Analysis and IQVIA sources, where indicated below

Notes: Geographic split based on customer billing address; (1) IQVIA CH Customized Insights European Market Data for CAGR 2022-2024 ; (2) IQVIA CH Customized Insights European Market Data for calendar year 2024; (3) IQVIA CH Customized Insights European Market Data for calendar year 2024 and IQVIA Eurasian CH Data for calendar year 2024; (4) CHC Local Hero Brands data is as of December 2024; (5) STADA internal assessment of Consumer Healthcare brands with high growth potential due to prevailing consumer brand awareness and dormant brand equity

Addressing the large, growing and resilient European Consumer Healthcare market



European Consumer Healthcare market (€bn)




Accelerating growth drivers



Increasing **proportion of older people** and population growth



Increased shift to **self-care and prevention**




Premiumization & innovation driving pricing

Delivering strong double-digit growth across Europe



STADA Consumer Healthcare Revenues (€bn)



Source: Company information

Note: (1) Based on Company's internal management reporting system or accounting records, unaudited and not reviewed by auditors. Revenues by country based on customer billing address

STADA's local operational focus is a competitive advantage

STADA's strategy

Typical industry strategy

Local vs. HQ 	Local entrepreneurship with lean headquarters		Central headquarters driven
Brand type 	Local Hero brands		Global brands
Brand activation 	Tailor-made to local customers		Global standards
Country focus 	Focus on all countries with positive RoI		Focus on largest markets
M&A strategy 	Local M&A strategy		Global M&A strategy
Synergies 	Synergies with Generics		Standalone CHC player

STADA's brand portfolio covers all main consumer health categories



Cough & Cold

- Nasal decongestant
- Cough relief
- Cold or flu remedies
- Sore throat relief

Derma

- Anti-dandruff
- Wound healing
- Baby skin care
- Specialist skincare
- Foot-care

Pain & Relief

- Antivaricose
- Muscular pain relief
- Topical and systemic remedies
- Joint health
- Oral pain

Gastro

- Laxatives
- Probiotics
- Digestive tract and stomach products
- Antidiarrheals & rehydration

VMS¹

- Mineral supplements
- Vitamins
- Nutritional supplements,
- Tonics & other stimulants
- Weight loss products

Other CHC

- Sleeping remedies
- Men & women health products
- Eye care
- Cardio
- Hygiene & disinfectants

Description


Select products



STADA with strong commercial infrastructure covering almost all countries in Europe as well as Eurasia and selected EM¹ covering est. ~100,000 pharmacies



STADA covers >40² countries with ~2,300 internal sales force FTEs³



Significant sales power & platform

~2,300 field force FTEs visiting our customers, esp. independent pharmacies (often joint field force with Generics)

Overproportionate presence in **fast-growing regions** such as Eastern Europe, Eurasia & selected Emerging Markets

STADA well positioned as **commercial go-to partner** for acquisitions, out-licensing, and commercial alliance agreements


Source: Company information as of December 2024
 Note: (1) Emerging Markets; (2) With a direct presence; (3) The graph shows # of internal sales force FTEs. Each region is standardized to 100% and the width represents the percentage distribution of internal sales force FTEs across regions. Within a region, the country with the highest percentage share of Internal Sales Force FTEs is listed first.

Nizoral: Reactivation of brand by impactful activation and portfolio expansion



Nizoral Revenues

CAGR 21-24 (%)



Source: Company information

Key drivers

- 1 2019 – Launch of international campaign



- 2 2023/24 – Line extensions: Daily range



- 3 2024 – Acquisition of Nizoral Cream in EMEA




Zoflora: UK's #1¹ homecare disinfectant brand and Top 5¹ Cleaning brand in the UK



Zoflora Revenues

CAGR 21-24 (%)



Key Launches

- 1 2021/22 Launch outside of disinfectant category with activation via digital channels



- 2 2023 Launch of floor and carpet cleaning products



- 3 2024 Launch of bathroom and toilet cleaning products




Source: Company information, Company Data Analysis
 Notes: (1) Company Data Analysis

Elotrans: From diarrhea to lifestyle – a popular hydration and electrolyte solution



Elotrans Revenues


CAGR 21-24 (%)



Key drivers

- 1 **1979 – Launch of Elotrans - German STADA heritage brand**
OTC solutions for **treating dehydration** resulting from diarrhea

ELOTRANS[®]



- 2 **2023 – Launching Elotrans Reload as food supplement**
Accelerating growth due to multi-channel sales & easier advertising

ELOTRANS[®]
reload



- 3 **As of 2024 - Elotrans Reload with presence in ~9 countries**




STADA's proven Local Hero playbook accelerates growth through localized strategies



STADA's brand acceleration levers

Select brand examples



STADA is the #1 deal maker in Consumer Healthcare¹ and partner of choice for those looking to divest brands



>200 brands acquired across all segments between 2018 and 2024



Critical M&A CHC Success Factors

- **Experienced integrator of brands** into broader platform
- **Proven playbook to imbue growth** into formerly neglected brands
- **Utilize STADA's commercial platform** to **strengthen** CHC portfolio of local hero brands
- **Strong TechOps capabilities** delivering cost synergies

19 CHC acquisitions²

2018	2019 & 2020	2021	2022	2023	2024
<p>sanofi Hedrin buy-back</p> <p>Jalf Nizoral Shampoo</p> <p>ALFASIGMA Ketodol</p>	<p>GSK GSK I "Violet"</p> <p>GSK GSK II "Elara"</p> <p>FERN-C</p> <p>WALMARK</p> <p>Takeda</p> <p>BAYER Orasept</p> <p>mundi pharma Hedrin buy-b. II</p>	<p>sanofi Sanofi brand Portfolio "Dragon"</p> <p>INNventa Inventive Pharma Solutions</p>	<p>PHARMOVAL</p> <p>Jalf Nizoral Cream</p>	<p>FemmaBiotic</p> <p>sanofi Sanofi brand Portfolio "Leopard"</p>	<p>sanofi Antistax Austria</p> <p>Jalf Nizoral Cream (APAC)</p>

Source: Company information; Biomedtracker

Note: Logos referring to counterparts or targets; years represent signing of agreement. (1) Closed deals between Jan-2018 and Dec-2024, geography defined as either buy side or sell side HQ, yearly allocation by announcement date; based on Biomedtracker; (2) Closed deals between Jan-2018 and Dec-2024, geography defined as either buy side or sell side HQ

Prime opportunity to wake-up a further >130 Sleeping Beauty brands

Selected Sleeping Beauty brands^{1,2}

Cough & Cold



Bronchokod

Pain & Relief



Mobilat

Gastro



frubiase

Derma



Psilo-Balsam

VMS



Degasin

Other



Prostenal

STADA's Sleeping Beauty playbook

>130

Sleeping Beauties


to be accelerated via proven playbook

- 1 Identify **neglected brands with dormant equity** (i.e., with high remaining brand awareness, strong positioning and positive brand values)
- 2 **Low invest activation trial** to identify degree of brand reactivity and prelude to drive RoI with higher investment
- 3 Gear up investment levels and **activate broad scale across relevant growth drivers** (distribution, visibility, detailing, media)
- 4 Accelerate growth by **launching line extensions** and thereby broaden brand relevance to additional consumer groups with objective of Sleeping Beauty to become a Local Hero brand


Product development is a differentiator for STADA and a key driver of growth in Consumer Healthcare



Revenue growth from launches



Launches by category 2024



Column width represents proportion of launches

Source: Company information

Note: (1) Defined on Group level as the portion of the Group's revenues or segment revenues within a given calendar year which can be clearly associated with launches in such calendar year plus the incremental revenue arising from launches in each of the two preceding calendar years. As launch, STADA considers the market introduction of a pharmaceutical or CHC product involving either (i) a country in which the product has not previously been marketed, or (ii) a new dosage form for a product, or (iii) a new strength for a product, or (iv) a combination of pharmaceutical molecules which has not previously been marketed

STADA's digital capabilities drive a high level of engagement with customers



Digital medium

Metric¹

Description


Example

>500m impressions p.a.

Local Hero Websites



Company & brand webpages tailored to engage with consumers and enable them to purchase on- or offline



Ad Accounts



Strong presence and partnerships with relevant platforms to maximize reach



Social Media Accounts




Strong localized representation across major platforms engaging with consumers



Country Mkt Dashboards



Local monitoring & KPI-based optimization to maximize ad effectiveness



Key Takeaways



1 | STADA is the **fastest-growing company among the top 10 global CHC players (2022-2024)¹**, ranked **#4²** in the attractive **€39bn European Consumer Healthcare market (2024)**


2 | Proven playbook with **>240 Local Hero brands** and the opportunity to wake up **>130 Sleeping Beauty brands**

3 | Ability to **drive growth via launches** and an **increasing share of e-commerce**

Appendix Generics



STADA – A leading Generics player in Europe and a growing business in Eurasia and Emerging Markets



8%

organic
Revenues CAGR
(2021-2024)

#4

player Europe,
leading position
in key markets¹

~85%

historic²+targeted³
Loss of Exclusivity
(LoE) coverage⁴

24%

segment
Adjusted EBITDA
margin

Symbioses

and shared
capabilities
betw. segments

**Country
specific**

GTM⁵ models,
driven by local
entrepreneurs

Sources: Based on Company Data Analysis and IQVIA source, where indicated below

Note: Revenues by country based on customer billing address. (1) IQVIA MIDAS European Generics Market Data for the calendar year 2024; (2) Average historical LoE coverage between 2019-2024; (3) See slide 54 – refers to expected coverage from 2025-2028;


(4) Targeted LoE coverage during upcoming wave of LoEs; (5) Go to market

STADA addresses the large, growing, complex, fragmented and highly attractive European Generics market




Large and growing market...

Gross sales by geography, €bn




...requiring deep local skill and localized GTM¹ approach...

Illustrative indication of influence of stakeholders



...and fragmented with competitive landscape

Market share by gross sales (2024)




Sources: Based on Company information; IQVIA MIDAS European Generics Market Data for calendar years 2019 to 2024
 Note: (1) Based on management view



Market growth is expected to accelerate based on a large profit pool of LoEs

European Generics market 2019-2028E, gross sales (€bn)




STADA is well positioned to take advantage from increasing Generics penetration



Generics penetration by country

Bn std. units of Generics vs. total volume (incl. non-Generics)




Untapped off-patent market

- **Generics** accounting for **~68%¹ of dispensed medicines** in Europe in 2024
- **Penetration growth momentum** expected to remain **intact**, in line with **cost-containment policies**, and driven by **catch-up effect** in several markets
- Countries with **lower penetration** such as **Italy, Belgium, Spain** with significant **room for growth** (markets traditionally very brand-conscious with patients having strong affinity for originators or known brands)
- With increasing Generics penetration, **larger share of off-patent market becomes addressable** for STADA

STADA is the #4 Generics player in Europe with a deliberate focus on retail Generics in attractive geographies



Generics Revenues (€bn)



Strong focus on Europe

- STADA is the **#4⁽³⁾ Generics player in Europe** with 8 top-3 positions across Europe and strongholds in Germany (#2), and Belgium (#1)
- Deliberate **focus on retail channel** with **above-average profitability** profiles contributing to top-line and bottom-line development


STADA with strong Generics platform across markets due to highly tailored GTM models and excellent local commercial execution



Retail segment only

Every market has local channel differences...

...requiring a differentiated approach to GTM strategy



Germany
Excellent central tender management, no Gx field force on the ground

Spain
Strong local presence across regions maintaining close relationships with pharmacies and wholesalers

Italy
Dual salesforce covering pharmacies and prescribers, broad use of external sales reps¹ to maintain flexibility

STADA's broad and comprehensive INN portfolio covers all therapeutic areas¹, with over 16k SKUs



	Nervous System & Pain	Cardiovascular	Alimentary Tract & Metabolism	Anti-Infectives	Urology & Sex Hormones	Musculo-Skeletal System	Respiratory System
Select indications	<ul style="list-style-type: none"> • Post-operative pain • Chronic back pain migraine • Anxiety 	<ul style="list-style-type: none"> • Hypertension • Angina • Heart failure 	<ul style="list-style-type: none"> • Diabetes mellitus • Gastric ulcers • Gastroesophageal reflux disease 	<ul style="list-style-type: none"> • Bacterial infections • HIV/AIDS • Tuberculosis 	<ul style="list-style-type: none"> • Urinary tract infections • Prostate hyperplasia • Infertility 	<ul style="list-style-type: none"> • Osteoarthritis • Rheumatoid arthritis • Osteoporosis 	<ul style="list-style-type: none"> • Asthma • Chronic obstructive pulmonary disease • Pneumonia
Select products							

Generics FY24 Revenues: €1.7bn

Key Takeaways



1 | **STADA** plays in the highly attractive European market: **Large (€27bn generics gross sales for 2024)¹**, accelerating in **growth (~5% CAGR '24-'28E)**, with **complex GTM framework** and thus **very profitable**


2 | **Leading positions in attractive and profitable markets** (#4 player across Europe, leading in key markets) leveraging **deep market understanding, localized GTM, comprehensive portfolio** and **strong supply/COGS**

3 | Positioned to **outperform the market in the mid-term**, building on **strong momentum, operational rigour** and **~85% targeted LoE coverage**

Appendix Specialty



STADA Specialty – Successfully developing and commercialising high-value treatments and delivering double-digit growth



Source: Company information

Note: (1) According to IQVIA, to qualify as specialty generics, prescription drugs must meet at least four of the following seven criteria: (i) high annual costs, (ii) initiated and maintained by a specialist drug therapy, (iii) practitioner administered, (iv) special procedure required (refrigerated, frozen, other biohazard), (v) reimbursement assistance required, (vi) limited distribution and (vii) extensive monitoring or comprehensive patient counselling required; (2) As of December 2024; (3) Oncology, immunology, bone health, nephrology, neurology and ophthalmology; (4) Apo-Go®, Kinpeygo®, Lecigon®, Corpos®; (5) Since April 2025, STADA markets 6 biosimilars (and not 7) due to termination of pegfilgrastim

STADA Specialty has broad expertise across therapeutic areas and proven ability to build new capabilities



Product category

Innovative

- Neurology: Advanced Parkinson’s Disease, Multiple Sclerosis
- Nephrology: Immunoglobulin A nephropathy (IgAN)

Example indications

Biosimilars

- Rheumatology: Rheumatoid Arthritis
- Gastroenterology: Crohn's Disease, Ulcerative Colitis
- Dermatology: Plaque Psoriasis, Psoriasis
- Nephrology: Anemia associated W. Chronic Renal Failure
- Oncology: Solid Tumors, Chemotherapy Induced Anemia
- Ophthalmology: Wet Age-related Macular Degeneration, Diabetic Macular Edema
- Bone Health: Osteoporosis (Increased Risk Of Fracture)

Specialty Gx (incl. branded Gx)


- Multiple Myeloma
- Chronic Myelogenous And Acute Lymphoblastic Leukemia
- Prostate Cancer
- Breast Cancer
- Anti HIV-1
- Diabetes
- Cardiovascular / Hypertension
- Pain Disorders

Example products




Dedicated Specialty M&S platform that is tailored to product/market needs and is ready to launch additional complex products

Go-to-market channels for STADA's Specialty portfolio¹



STADA Specialty M&S Footprint⁴





Source: Company information

Note: (1) Based on management view; (2) Incl. Switzerland, Austria, Netherlands, Belgium, Nordics; (3) Incl. Poland, Romania, Serbia, Slovenia, Czech Republic, Bulgaria, Slovakia; (4) Excludes external salesforce; incl. Britannia Pharmaceuticals Ltd.; FTE as of December 2024

Lecigon and Kinpeygo demonstrate STADA's ability to launch complex innovative therapies and establish new standards of care



	Lecigon®	Kinpeygo®
Launch partner & competitive edge	 <p>Advanced Parkinson's disease Acquisition from Lobsor Pharmaceuticals (2020)</p>	 <p>Immunoglobulin A nephropathy (IgAN) Exclusive licensing agreement with Calliditas (2021)</p>
Key success factors	Key drivers	Key drivers
Broad coverage of EU prescriber base	<ul style="list-style-type: none"> ✓ So far launched in 19¹ countries ✓ Further launches planned in 2024 and beyond 	<ul style="list-style-type: none"> ✓ Launched in DE, further tiered launches planned in high-potential European markets
Strong market access & regulatory capabilities	<ul style="list-style-type: none"> ✓ Rapid scale-up in early launch markets (AT, CH, RO) 	<ul style="list-style-type: none"> ✓ Approval as first IgAN treatment in Europe, already one year after licensing and successful expansion of label to address larger patient pool ✓ Successful pricing & reimbursement in Germany and the UK
Strong launch capabilities & track record	<ul style="list-style-type: none"> ✓ Launch within 5 months after acquisition 	<ul style="list-style-type: none"> ✓ Fast initial launch of Kinpeygo® in DE
Deep TA expertise	<ul style="list-style-type: none"> ✓ Focus on advanced Parkinson's (coverage of 100% movement disorder centers & PD1 specialists) ✓ APO-go pen/pod already cover parts of on-demand therapy & advanced cont. treatments 	<ul style="list-style-type: none"> ✓ Strong prescriber field force already active in DE ✓ STADA engages closely with leading experts / KOLs and supports the advancement of guidelines incl. positioning of Kinpeygo® as treatment option
Early & strong relationship with the partner	<ul style="list-style-type: none"> ✓ Strong partnership and seamless integration of Lobsor Pharmaceuticals product 	<ul style="list-style-type: none"> ✓ Partnership with Calliditas and signing of in-licensing agreement for Europe with ongoing best-practice sharing

STADA is evaluating a large funnel of opportunities for additional launch of innovative therapies



STADA's Innovative opportunity screening criteria



STADA with **well-defined framework** for the selection of opportunities in the market
 Approach ensures STADA's focus on **strong and close-to-launch assets** within **focused but attractive segments**

Key Takeaways



1 | Specialty is the **fastest-growing and strongly profitable** segment within STADA and includes the product categories **Innovative, Biosimilars** and **Specialty Generics**

2 | STADA's Specialty **platform at-scale** is ready to take advantage of favorable secular trends to **launch** many more **products** globally

3 | Track record of **drug development, market access and commercialization** success, along with pan-European presence, position STADA as a **partner-of-choice**


Appendix Governance & ESG



STADA is institutionalizing growth culture across the organization at all levels




Examples how culture is hard-wired throughout STADA



STADA+

Growth mindset vehicle for identification & execution of high RoI initiatives and business cases

add. EBITDA upside




Performance management

STI¹ schemes for managerial employees are steeply tailored in line with pay for performance

25% STI Value goals


Examples how culture is soft-wired throughout STADA



#CaringForYou

Broad range of initiatives offered to care for employees and strengthen both mental and physical health & wellbeing

+8%² higher productivity






STADA Expo

Modern employer branding tool to highlight STADA's differentiated employee growth proposition

10 cities 5 countries visited


Culture drives performance at STADA



Source: Company information

Notes: (1) Numbers based on pulse survey May 2025; (2) Healthcare External benchmark based on: Qualtrics benchmark EXM Methodology; (3) No Healthcare External Benchmark available, therefore used Global All Industry External Benchmark based on: Qualtrics benchmark EXM Methodology

Board of Directors based on Dutch Corporate Structure with an Independent Chairman




We envision a **well-rounded Board of Directors** that mirrors STADA's commitment to excellence and innovation, **aligning with best corporate governance practices**, including those outlined in the Dutch Corporate Governance Code

- ✓ In line with **recommendations of the Dutch Corporate Governance Code**
- ✓ **Extensive experience** across Healthcare industry
- ✓ **Independent Chairman**
- ✓ **3/9 independent Board members**
- ✓ **4/9 Shareholder representatives¹**
- ✓ **7/9 non-executive directors**
- ✓ **Audit and Remuneration Committees** at board level will be **chaired by independent directors**

STADA is on track to achieve ambitious ESG targets



2024: 65%
>65%
renewable electricity by 2025



2024: 0.35
<0.30
Lost Time Incident Rate (LTIR) by 2025




2024: -34%
42%
reduction of GHG emissions by 2030
(compared to 2020)



2024: 80%
>90%
of spend (direct category) covered by
EcoVadis rating in 2025¹



2024: 51%
≥50%
women in management positions



2024: 97%
≥97%
completion rate of compliance trainings
by 2025

Source: Company information, STADA Sustainability Report 2024
Notes: (1) direct category (all CMOs, API, excipient and packaging material supplies)

STADA has strong ESG ratings confirming our strong risk management processes and low ESG risk exposure

Sustainalytics ESG rating¹



17.5 Sustainalytics ESG risk rating score
(**Low ESG risk**)

Strong ESG risk management (62.5)

#3rd percentile within **Pharmaceuticals** (8th out of 418 companies)²

STADA Arzneimittel AG

Pharmaceuticals Germany

ESG Risk Rating

17.5

Last Full Update Dec 5, 2023


-0.6

Momentum

Low Risk



ESG Risk Rating Distribution



ESG Risk Rating Ranking

UNIVERSE	RANK (1 st = lowest risk)	PERCENTILE (1 st = Top Score)
Global Universe	2561/14377	19th
Pharmaceuticals Industry	37/848	5th
Pharmaceuticals Subindustry	8/418	3rd

EcoVadis ESG rating³



76/100 EcoVadis overall ESG score
(**Advanced ESG score**)


Strong ESG scoring in all 4 ESG categories
(≥ 70)

Top 2% of **Pharma** companies rated by EcoVadis⁴


Sustainability performance: Insufficient, Partial, Good, Advanced, Outstanding, Average score



Overall score distribution



Theme score comparison



Source: Sustainalytics

Note: (1) Rating as last update by Sustainalytics July 24, 2025 of STADA Arzneimittel AG covering 8 ESG categories. Sustainalytics is a leading ESG research provider, who provides research based on its independent methodology, and publicly available information or non-confidential information from issuers; (2) Pharmaceuticals sub-industry: Companies engaged in the research, development, or production of pharmaceuticals

Source: EcoVadis

Note: (3) Rating as of December 17, 2024 of STADA Arzneimittel AG covering 4 ESG categories. EcoVadis is a leading Sustainability rating company, who provides rating based on its independent methodology, and publicly available information or non-confidential information from issuers; (4) Pharma companies: Companies rated by EcoVadis in the Manufacture of basic pharmaceutical products and pharmaceutical preparations industry.

STADA's ROI driven make-or-buy decision process ensures competitive COGS

Share of COGS¹

Key pillars for competitive COGS

External Sourcing



FD²:
Out-standing savings engine

- **External Supply Organization (ESO)** deployed **globally**
- "**External as internal**" mindset
- Strong **alliances** and relationships
- Balance between **local & global supplier landscape**
- Expanded move to **source from best cost countries**

Internal Manufacturing




Production materials:
Strict category management

- Competitive **purchasing excellence**
- **Category leads** (APIs, excipients, raw materials)
- **Central procurement** to drive scale and relationship
- Leveraging **dual sourcing** strategy

Internal sites:
Best-cost locations & rigorous management

- **Low-cost locations**
- **High utilization** of assets
- Full deployment of **STADA Production Systems**
 - Opex culture
 - Lean concepts
 - Visual factory

Others






Above site cost and other (e.g., write-offs)

- **Best-cost country hub** approach for routine TechOps process execution
- Global Quality and Technical Teams to **secure compliance and supply**
- Central Demand planning/inventory management to support Sales and **minimize write offs**

STADA's global manufacturing network focuses on "best-cost countries"



STADA internal manufacturing sites



Site	Country	CHC	Gx	Sx	
1 Bad Vilbel		✓	✓	⊘	✓
2 Uetersen	Germany			✓	
3 Huddersfield	UK	✓	✓		
4 Preston		✓			
5 Tulln	Austria	✓			
6 Vrsac PC ¹		✓	✓	⊘	✓
7 Sabac	Serbia	✓	✓	⊘	✓
8 Vrsac/Dubovac		✓	✓		
9 Tuy Hoa PME 1	Vietnam	✓	✓		✓
10 Tuy Hoa PME 2		✓	✓		✓
11 Trinec	Czech	✓			✓
12 Podgorica	Montenegro	✓	✓	⊘	
13 Miyun	China		✓		✓
14 Bila Tserkva	Ukraine	✓	✓	✓	
15 Turda PC ¹	Romania	✓	✓	⊘	✓
16 Banja Luka	Bosnia	✓	✓	⊘	✓


⊘ High-cost country
 ⊘ "Best-cost" country
 Packaging capabilities
⊘ Light grey tick marks for <10% of site conversion cost allocated to specific segment

Source: Company information
 Note: (1) Only packaging

STADA's six quality hubs drive "no failure culture" and supply resilience




Quality footprint ready to support future growth ...




... and track record of no failure culture

Inspection record shows zero EU/US internal manufacturing site audit failures '21-'23¹



Only 27 product quality recalls '21-'23



Source: Company information
Note: (1) Audits by EU authorities / FDA with zero critical audit findings

Appendix Financials







Broad geographic footprint with vast majority of countries growing strongly

Revenues by country (€m) – 2024^{1,2}

% of Group Revenues



CAGR 2021 – 2024



Comments

- **Long list of countries** with scale and strong growth over the past years
- Strong presence across **Western Europe** and **Eastern Europe**
- Selective presence in **fast-growing Emerging Markets** (e.g. Kazakhstan/Eurasia, Vietnam, Serbia, Gulf and Saudi Arabia)

Source: Company information


Note: (1) Based on Company's internal management reporting system or accounting records, unaudited and not reviewed by auditors; (2) Revenues by country based on customer billing address; (3) ROW includes among other revenues with Russia as this purely relates to CMO business as well as API sales into the US



Diversified portfolio with no product larger than 4% of Group Revenues

Revenues by product – 2024^{1,2}

% of Group Revenues



Comments


- **CHC with over 1,000 products** (in the sense of brand or API-name), thereof 241 brands with #1-#3 position in their country-category
- **Generics with over 600 products** (INNs) across vast area of Therapeutic Area and strong launch-track record
- **Specialty with over 300 products with Biosimilar Silapo®/Epoetin** as largest product (including royalties), newly launched biosimilars **Oyavas®** and **Hukyndra®** and innovative Parkinson-treatment **Lecigon®** already in top 5

Source: Company information

Note: (1) Based on Company's internal management reporting system or accounting records, unaudited and not reviewed by auditors; (2) Revenues by Product with product defined as combination of SKUs using the same API or brand name and assigned to same "Profit Center" as per SAP Management Reporting system

Key foreign currencies and assumptions behind guidance for 2025 – STADA with relatively limited FX-exposure

Revenue in 2024 by currency (% of total)



Assumed currency rates behind Guidance 2025 €-values

For the purpose of the Profit Forecast 2025, the Group assumes the following currency rates for its primary foreign currency exposure in Financial Year 2025:

Currency rate	For the Financial Year ending December 31, 2025
USD/EUR	1.08
RUB/EUR	104.00
RSD/EUR	117.05
GBP/EUR	0.83
CHF/EUR	0.93

Mainly transactional, no entity in respective country

- **Over 60% of Revenues** from entities with EURO as functional currency
- Other currencies making less than 8% each of group revenue, therefore **translational currency exposure limited**
- **Transactional currency** exposure to additional currencies such as USD (e.g. royalty revenues from US, procurement from US), RUB (CMO Export sales) and others
- Guidance €-values based on **assumed rates as stated here**



P&L: Continuous growth of revenues and EBITDA

in €m	2023	2024	Growth	1H'24	1H'25	Growth
Revenues	3,735	4,059	+9%	2,013	2,123	+5%
Cost of sales	2,119	2,321	+10%	1,140	1,182	+4%
Gross Profit	1,616	1,738	+8%	873	941	+8%
Adjusted Gross Profit	1,844	1,973	+7%	989	1,059	+7%
Adjusted Gross Margin	49.4%	48.6%	-0.8ppt	49.1%	49.9%	+0.8ppt
Selling expenses	791	814	+3%	407	442	+8%
General and administrative expenses	285	290	+2%	144	159	+10%
Research and development expenses	97	107	+10%	54	58	+8%
OPEX	1,173	1,210	+3%	605	659	+9%
Other expenses / (income), thereof:	77	21	-72%	9	17	+83%
- impairments/write-ups on non-current assets	11	(20)		3	11	
- litigation expenses	78	40		19	7	
D&A ¹ , thereof:	358	334	-7%	178	193	+9%
- D&A from purchase price allocation including product acquisitions	228	235		116	119	
Investment / At equity result	0	0	+31%	0	0	+210%
EBITDA	724	840	+16%	436	458	+5%
Adjusted EBITDA	784	874	+11%	456	461	+1%
Adjusted EBITDA margin	21.0%	21.5%	+0.5ppt	22.6%	21.7%	-0.9ppt
Adjusting for currency effects	12	12	+0%	1	20	
Adjusted cc. EBITDA	796	886	+11%	457	481	+5%
Adjusted cc. EBITDA margin	21.3%	21.8%	+0.5ppt	22.7%	22.6%	-0.1ppt

- **Continuous strong topline-growth** in all three segments
- **Adj. Gross Margin** with slight margin-reduction driven by adverse product mix (lower Cough & Cold volumes) and start-up cost of new Romanian packaging site in FY24.
- **Considerable adj. gross margin expansion** of 80bps in H1 2025
- **Operating expenses** with strong operating leverage on G&A and field force, impacted by one-time expenses in 1H'25.
- **Other expenses** comprised mainly of impairment and litigation expenses
- **Strong expansion** of Adj. EBITDA and Adj. cc EBITDA margin in 2024

Gross Profit Adjustments: Mainly PPA effects

(in €m)	2021	2022	2023	2024	1H'24	1H'25
Gross Profit	1,177	1,419	1,616	1,738	873	941
Effects from purchase price allocation and product acquisitions	1 226	228	228	235	116	119
Other	2 (2)	-	-	-	-	0
Adj. Gross Profit	1,401	1,647	1,844	1,973	989	1,059

1 Relates to the elimination of subsequent measurement effects of fair value step-ups included in the consolidated income statement of items initially recognized in purchase price allocations in connection with business combinations and significant product acquisitions

2 Relates to inventory remeasurement effects not deemed operational, primarily consisting of reversals of inventory write downs relating to significant patent litigations as well as expenses for the IT transformation for our S/4 Hana roll-out¹

EBITDA adjustments: Minor adjustments to ensure better view of underlying performance

(in €m)	2021	2022	2023	2024	1H'24	1H'25
EBITDA	577	677	724	840	436	458
Effects from purchase price allocation and product acquisitions	1 (29)	(13)	(2)	(9)	(2)	-
Reversals of provisions for damages	2 (7)	-	-	-	-	-
Income and expenses in connection with the takeover process	3 0	0	72	18	4	(3)
Other	4 -	-	(9)	24	18	6
Adj. EBITDA	541	664	784	874	456	461

- 1** EBITDA adjustments for **Purchase Price allocation effects** mainly related to valuation-effects on the Earn-Out component of the Lobsor/Lecigon acquisition in 2020 (additional PPA effects within Gross Profit)
- 2** Primarily consisting of reversals of **provisions for damages** and reversals of related inventory write-downs
- 3** Relates mainly to income and expenses for **provisions for legal disputes** in connection with the **takeover of STADA Arzneimittel AG** and the conclusion of a profit and loss transfer agreement with Nidda Healthcare Holding GmbH in 2017
- 4** Relates to **miscellaneous extraordinary income and expenses**, in 2024 mainly litigation expenses, IT transformation costs for the S/4 Hana Roll-out and expenses in connection with exit activities. In 1H'25, this additionally relates to gains and losses from significant business disposals as well as severance expenses

Consolidated income statement (€m)

	2021	2022	2023	2024	1H'24	1H'25
Revenues	2,852	3,298	3,735	4,059	2,013	2,123
Cost of sales	1,675	1,879	2,119	2,321	1,140	1,182
Gross profit	1,177	1,419	1,616	1,738	873	941
Selling expenses	633	732	791	814	407	442
General and administrative expenses	217	252	285	290	144	159
Research and development expenses	80	85	97	107	54	58
Other income	88	81	118	84	33	33
Other expenses	337	335	195	105	42	50
Operating profit	(1)	96	365	506	259	265
Share of net profit of investments accounted for using the equity method	0	(0)	0	0	0	0
Financial income	11	54	76	102	55	10
Financial expenses	247	261	498	607	300	335
Financial result	(235)	(207)	(422)	(505)	(246)	(325)
Earnings before taxes	(237)	(111)	(57)	1	13	(60)
Income taxes	7	58	67	126	13	43
Result from continuing operations	(244)	(169)	(124)	(125)	0	(104)
Result from discontinued operations	53	46	(646)	—	—	—
Result of the period	(190)	(123)	(770)	(125)	0	(104)
thereof						
attributable to Nidda German Topco GmbH (net income) from continuing operations	(266)	(195)	(155)	(156)	(18)	(118)
attributable to Nidda German Topco GmbH (net income) from discontinued operations	53	46	(646)	—	—	—
Total attributable to Nidda German Topco GmbH	(212)	(149)	(802)	(156)	(18)	(118)
attributable to non-controlling interest from continuing operations	22	26	31	31	18	14
attributable to non-controlling interest from discontinued operations	—	—	—	—	—	—
Total attributable to non-controlling interest	22	26	31	31	18	14

- Over-proportionate **gross profit** growth in H1 2025 based on price increases and strong TechOps performance & procurement savings
- **Selling Expenses** increased by 8.5% in H1 to support launches
- **General and administrative expenses** increased moderately due to one-time effects relating to IT investments (SAP S4/Hana) and the contemplated transaction
- **Financial expenses** in H1 2025 reflect the pre-transaction capital structure and €[18]m one-off expenses for the bond refinancing in May
- Interest expenses currently **not fully tax deductible under pre-transaction** capital structure (*Zinsschranke, interest barrier*); normal tax rate expected in 2026

IFRS Balance Sheet



Consolidated balance sheet - Assets (€m)

Assets	2021	2022	2023	2024	1H'25
Non-current assets	5,551	5,234	4,471	4,532	4,395
Intangible assets	4,862	4,500	3,686	3,584	3,467
Property, plant and equipment	622	630	607	645	623
Financial assets	18	13	3	2	8
Investments accounted for using the equity method	3	3	2	2	2
Other financial assets	0	20	101	220	211
Other assets	4	7	9	9	9
Deferred tax assets	42	61	64	70	74
Current assets	2,299	2,254	2,225	2,326	2,425
Inventories	812	965	1,098	1,082	1,174
Trade receivables	763	879	731	793	845
Contract assets	—	—	—	20	18
Return assets	1	1	1	1	0
Income tax receivables	38	32	26	22	28
Other financial assets	16	24	92	61	35
Other assets	74	82	84	87	121
Cash and cash equivalents	594	270	194	256	204
Non-current assets and disposal groups held for sale	—	—	—	4	—
Total assets	7,850	7,488	6,696	6,858	6,820

- **Inventory increase in 2023** due to deliberate investment to secure supply reliability, in 2024 decrease due to a normalization of global procurement market and the high level of supply stock in prior year. Temporary inventory investment in H1'25 due to launches and seasonal products
- **Other financial assets** increased due to loans receivables towards formerly consolidated Russian subsidiary and derivative financial assets (embedded options)
- Note that **2022 balance sheet** values still contain the de-consolidated Russian subsidiaries (separated in September 2023)

IFRS Balance Sheet (cont'd)



Consolidated balance sheet - Equity & Liabilities (€m)

Equity & Liabilities	2021	2022	2023	2024	1H'25
Equity	(215)	(330)	(1,142)	(1,318)	(1,490)
Subscribed capital	0	0	0	0	0
Capital reserve	1,180	1,172	931	902	893
Retained earnings including net income	(1,456)	(1,602)	(2,410)	(2,569)	(2,687)
Other reserves	(33)	7	239	249	221
Equity attributable to shareholder of the parent company	(309)	(423)	(1,240)	(1,418)	(1,574)
Shares attributable to non-controlling interest	94	93	98	100	84
Non-current liabilities	6,651	6,219	6,258	6,520	6,498
Other provisions	39	33	102	87	34
Financial liabilities	5,684	5,286	5,334	5,615	5,690
Contract liabilities	—	—	12	10	10
Other financial liabilities	135	133	135	135	132
Other liabilities	4	4	2	5	6
Deferred tax liabilities	788	763	673	669	627
Current liabilities	1,414	1,599	1,580	1,656	1,811
Other provisions	20	24	25	71	114
Financial liabilities	376	342	326	281	343
Trade payables	594	689	695	746	767
Contract liabilities	1	5	2	2	3
Income tax liabilities	64	97	88	94	146
Other financial liabilities	201	244	251	257	266
Other liabilities	157	199	194	205	173
Total equity and liabilities	7,850	7,488	6,696	6,858	6,820

- **Other provisions** (current/non-current), since FY23 mainly include the provision for the legal dispute in connection with the takeover of STADA Arzneimittel AG. The book value amounts to €80m as of 1H'25, entirely included in current provisions.
- **Financial Liabilities:** refinancing activities executed in 2024 and 1H'25 leading to extension of maturities to 2030 for term loans and bonds

IFRS Cash Flow Statement



Consolidated Cash Flow statement (€m)

	2021	2022	2023	2024	1H'24	1H'25
Result from continuing operations	(244)	(169)	(124)	(125)	0	(104)
Depreciation, amortization and impairments net of reversals of impairments of intangible and tangible assets	578	580	358	334	178	193
Income taxes	7	58	67	126	13	43
Income tax paid	(89)	(80)	(90)	(143)	(39)	(64)
Income tax received	21	4	8	14	2	24
Financial income and financial expenses	235	207	422	505	246	325
Interest received	1	1	2	2	1	1
Dividends received	0	0	0	0	—	—
Share of net profit of investments accounted for using the equity method	(0)	0	(0)	(0)	(0)	(0)
Result from the disposal of non-current assets	(4)	(0)	(11)	(3)	(1)	(19)
Additions to/reversals of other non-current provisions	7	3	6	23	4	1
Currency translation gains and losses	14	3	11	12	1	20
Other non-cash income and expenses	195	268	355	276	206	199
Gross Cash Flow	721	876	1,006	1,021	611	620
Changes in inventories	(8)	(217)	(322)	(72)	(25)	(153)
Changes in trade receivables	(49)	(92)	(80)	(64)	(72)	(62)
Changes in trade payables	39	125	46	29	(9)	17
Changes in other net assets, unless attributable to investing or financing activities	(210)	(161)	(204)	(197)	(184)	(228)
Cash Flow from operating activities from continuing operations	493	531	446	717	320	193
Cash Flow from operating activities from discontinued operations	119	168	115	—	—	—
Cash Flow from operating activities (total)	612	699	561	717	320	193

- **Operating Cash Flow generation** in previous years based on strong EBITDA increase (adjusted for material non-cash effects)
- Increasing **Net Working Capital** in previous years due to deliberate inventory build-up; with inventory normalization in 2024. Temporary inventory investment in 1H'25 due to launches and seasonal effects.

IFRS Cash Flow Statement (cont'd)

Consolidated Cash Flow statement (€m)

	2021	2022	2023	2024	1H'24	1H'25
Payments for investments in:						
intangible assets	(233)	(163)	(163)	(130)	(56)	(56)
property, plant and equipment	(69)	(58)	(97)	(80)	(35)	(26)
financial assets	(1)	(0)	(0)	—	-	(7)
business combinations in accordance with IFRS 3	(4)	(14)	(4)	(6)	(3)	(3)
Proceeds from the disposal of:						
intangible assets	1	19	20	4	2	22
property, plant and equipment	2	2	1	3	1	3
financial assets	—	—	—	—	—	—
shares in consolidated companies	—	5	5	5	3	—
Proceeds from government grants	—	—	—	12	—	3
Payments for loans granted	—	—	—	(6)	(4)	(3)
Proceeds for loans granted	53	105	—	45	45	38
Interest received for loans granted	9	7	—	4	4	2
Cash Flow from investing activities from continuing operations	(242)	(97)	(239)	(151)	(43)	(27)
Cash Flow from investing activities from discontinued operations	(66)	(146)	(79)	—	—	—
Cash Flow from investing activities (total)	(308)	(243)	(318)	(151)	(43)	(27)
Proceeds from financial liabilities	594	289	1,100	1,928	210	1,607
Repayment of financial liabilities	(279)	(575)	(908)	(1,874)	(228)	(1,545)
Payments related to the prolongation of bonds	—	(117)	(0)	—	—	—
Repayment of lease liabilities	(24)	(28)	(30)	(32)	(16)	(18)
Payments for interest rate derivatives	—	—	(20)	—	—	—
Proceeds from interest rate derivatives	—	—	16	13	8	0
Interest paid	(220)	(253)	(404)	(478)	(233)	(232)
Dividends paid to non-controlling interest	(24)	(27)	(27)	(29)	(4)	(4)
Changes in capital reserve	(4)	(8)	(3)	(32)	—	(19)
Changes in non-controlling interest	(3)	(15)	—	—	—	—
Cash Flow from financing activities from continuing operations	40	(735)	(275)	(504)	(263)	(212)
Cash Flow from financing activities from discontinued operations	(35)	(56)	(28)	—	—	—
Cash Flow from financing activities (total)	6	(790)	(303)	(504)	(263)	(212)
Changes in cash and cash equivalents	310	(334)	(60)	62	15	(46)
Changes in cash and cash equivalents due to the scope of consolidation	1	—	—	—	—	—
Changes in cash and cash equivalents due to currency translation	5	10	(17)	1	0	(7)
Net change in cash and cash equivalents	316	(324)	(76)	63	15	(53)
Balance at beginning of the period	278	594	270	194	194	256
Balance at end of the period	594	270	194	256	209	204

- **Investments in intangible assets** in 2023 include acquisition of CHC product portfolio from Sanofi
- **Proceeds** from the **disposal of intangible assets** in 1H'25 include the sale of the CHC product Polytar.
- **Investments in property, plant and equipment** for a new packaging site in Turda, Romania leading to an increased level in 2023 and 2024
- Higher payments for **interests** due to increasing interest rates

Modelling guidance – from Adj. cc EBITDA to Adj. Net Income



Item (€m)	Explanation / components	2023	2024	H1 2025	2025 forecast	Mid-term guidance
Adj. CC EBITDA	EBITDA adjusted for special items and currency effects¹	796	886	481	€930m-€990m	Mid-term-guidance: Growing faster than Revenues (which is guided to grow in mid- to high-single-digit percentage range)
<i>Growth vs. PY in %</i>			11.2%	5.2%		
Currency effects	EBITDA-effects from currency fluctuation	(12)	(12)	(20)		
Adj. EBITDA	EBITDA adjusted for special items	784	874	461		
Special items	EBITDA-effects from Special items:	(60)	(34)	(3)		
	1) effects from purchase price allocation and product acquisitions	2	9			
	2) reversals of provisions for damages	-	-			
	3) income and expenses in connection with the takeover of STADA by Bain and Cinven	(72)	(18)	3		
	4) other miscellaneous extraordinary income (+) and expenses (-)	10	(24)	(6)		
EBITDA	EBITDA reported	724	840	458		
Depreciation/ amortization	Total	(348)	(353)	(182)		
	- thereof from purchase price allocation and product acquisitions (a)	(228)	(235)	(119)		Similar to 2024 levels
	- thereof all other Depreciation/amortization	(120)	(118)	(63)		Around 3% of Revenues
Impairment losses and reversals	Total	(11)	20	(11)		
	- thereof impairment losses (b)	(74)	(25)	(11)		
	- thereof reversal of impairment losses (c)	63	45	-		
Financial result	Financial result:	(422)	(505)	(325)		
	- thereof nominal (net) interest expenses to third party lenders	(405)	(438)	(200)		2026 onwards less than ~€150m p.a.
	- thereof re-financing / transaction-related one-time financial expenses ² (d)	-	(19)	(18)		2026 onwards insignificant
	- thereof other financial expenses (incl. embedded options, amortized expenses and other non-cash effects) (e)	(6)	(34)	(101)		Non-cash accounting valuation effects only - no guidance provided
	- thereof leasing and factoring expenses	(12)	(15)	(7)		Under (€30)m p.a.
Income taxes	Income taxes include current and deferred taxes	(67)	(126)	(43)		Between 25% and 27% on Earnings Before Tax
Net Income	Result from continuing operations (reported)	(124)	(125)	(104)		
	(new) add back Special items within EBITDA	60	34	3		
	(a) add back Amortization of purchase price allocation	228	235	119		
	(b + c) add back impairment losses and reversal of impairment losses	11	(20)	11		
	(d + e) add back embedded options & one-off amortization within financial result	5	53	119		
	Add back corresponding income-tax-effect on above add-backs (assumed 25% effective tax rate)	(76)	(75)	(63)		calculatory tax effect
Adj. Net Income	Result from continuing operations, adjusted for PPA Amortization (a), Impairment effects (b & c), valuation effects from embedded derivatives & amortization within financial result and other non-cash effects (d & e), special items and corresponding income-tax effects on the above add-backs	104	102	85		

Source: Company information

Note: (1) Defined as net nominal interest expense to third party lenders, without one-time costs. Guidance assumes partial re-financing of existing instruments at the end of Q4 2025, EURIBOR similar to 2025 and margins in the mid-range. Expenses in 2025 still with a few months of higher debt & interest; (2) One-time cash expenses such as call premia for re-payment of existing bonds & loans

Modelling guidance – from Adj. CC EBITDA to Core Free Cash Flow



€m	2023	2024	H1 2025	2025 Guidance	Mid-term assumptions
Adj. CC EBITDA	796	886	481	~€930m to ~€990m	As per mid-term guidance for Adj. CC EBITDA
Currency effects	(12)	(12)	(20)	No guidance	No guidance
Adj. EBITDA	784	874	461		
Special item adjustments	(60)	(34)	(3)	No guidance	No guidance
Income tax paid ¹	(90)	(143)	(64)	Between €160m and €170m p.a. netted income tax paid	Between €160m and €180m p.a. No significant refunds expected
Income tax received	8	14	24		
Other non-cash income and expenses	355	276	199	A and B expected to roughly offset each other	A and B expected to roughly offset each other
<i>thereof Health Insurance Rebates accruals</i>	<i>197</i>	<i>174</i>	<i>143</i>		
<i>all other</i>	<i>159</i>	<i>102</i>	<i>56</i>		
Other reconciling items to gross cash flow	8	34	2	No guidance	No guidance
Gross cash flow	1,006	1,021	620		
in % of Adj. EBITDA	128%	117%	134%		
Change in inventories	(322)	(72)	(153)	Change in Net Working Capital amounting to around 3.0 to 4.0% of 2025 Revenues	Change in Net Working Capital each year developing from around 3.0% to 3.5% of respective year's Revenues
Change in trade receivables	(80)	(64)	(62)		
Change in trade payables	46	29	17		
Subtotal: NWC	(356)	(107)	(199)		
NWC change as % of Revenue	-9.5%	-2.6%	-9.3%		
Change in other net assets, unless investing or financing activities	(204)	(197)	(228)	A and B expected to roughly offset each other	A and B expected to roughly offset each other
<i>thereof Health Insurance Rebate payments</i>	<i>(183)</i>	<i>(178)</i>	<i>(148)</i>		
<i>all other</i>	<i>(20)</i>	<i>(19)</i>	<i>(80)</i>		
Cash flow from operating activities from continuing Operations	446	717	193		
in % of Adj. EBITDA	57%	82%	42%		
Payments for investments in property, plant and equipment , net of gov. grants	(97)	(69)	(24)	Core CAPEX expected to be around 5% of Revenues (including deals signed as of 31 July 2025)	Core CAPEX expected to be developing from around 4.5% to 4.0% of Revenues
Payments for intangible assets , financial assets and business combinations in accordance with IFRS 3 (excluding M&A assets greater than €50 million and BD&L assets greater than €50 million)	(91)	(136)	(66)		
Proceeds from the disposals of property, plant and equipment, intangible assets, financial assets and shares in consolidated companies	25	12	25		
Subtotal: Core CAPEX	(163)	(193)	(64)		
Core CAPEX as % of Revenue	-4.4%	-4.8%	-3.0%		
Proceeds and interest received or payments for loans granted	0	42	37	No guidance	No guidance
Core Free Cash Flow	283	566	166		
in % of Adj EBITDA	36%	65%	36%		

Source: Company information

Note: (1) Income tax paid in 2024 includes one-time tax refund of €16m